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Introduction 
 
Chronic Myelogenous Leukemia  
 
Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the 
hematopoietic stem cell (HSC). CML makes up approximately 15% to 20% of all cases 
of leukemia, with an incidence of 1 to 1.5 cases per 100,000 population per year (1). 
Similar to other myeloproliferative disorders, CML is usually triphasic, having a 
chronic, an accelerated, and a blast phase (2). In the initial chronic phase, myeloid 
progenitors and mature cells accumulate in the blood and extramedullary tissues;  in 
half of the patients the disease progresses directly from the chronic to the blastic phase 
characterized by a maturation arrest in the myeloid or lymphoid lineage (3). The main 
functional changes that occur with progression of CML are marked changes in 
proliferation, differentation, apoptosis and adhesion (4). CML is characterized by 
deregulated proliferation of cells of the myeloid lineage, in which leukemic blasts 
display a distinctive shortened chromosome, the Philadelphia (ph) chromosome 
generated from a reciprocal t(9:22) (q34:q11) translocation (5)(Fig. 1).  
 
 
 
Fig. 1: Reciprocal t(9:22) translocation in Chronic myeloid leukemia generate Philadelphia 
 chromosome 
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This translocation results in the head-to-tail fusion of the breakpoint cluster region 
(BCR) gene on chromosome 22 with the ABL proto-oncogene on chromosome 9 (6). 
The encoded chimeric bcr-abl oncoprotein exhibits constitutively active tyrosine kinase 
activity as a result of oligomerization of the coiled coil region of p210BCR/ABL (7) and 
deletion of the inhibitory SH3 domain of ABL (8). This results in the activation of a 
number of downstream signaling cascades (9). The targets for bcr–abl include members 
of the Ras, phosphotidylinositol-3 kinase (PI3K)⁄Akt, and Jak⁄Stat signaling pathways, 
which regulate cell proliferation and apoptosis. Bcr–abl abrogates cell dependence on 
external growth factors by upregulating interleukin-3 production and alters the cell 
adhesion properties by modulating expression and activation of focal adhesion kinase 
and associated proteins. (10,11).  The features of chronic phase CML, expansion and 
premature circulation of the malignant myeloid population can therefore be explained 
by activation of mutagenic pathways, antiapoptotic pathways and abnormal cytoskeletal 
function (Fig. 2). 
 
Fig. 2: Schematic representation of some signal transduction pathways activated by BCR-ABL 
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These same characteristics, increased mutagenicity and decreased susceptibility to 
apoptosis ay also be responsible for disease progression (12). Moreover, leukemic 
progenitors can acquire secondary aberrations that make them able to overcome cell 
cycle checkpoints and acquire an advantage in growth compared to normal cells and 
make them resistant to drug therapies.  
 
Therapy for Chronic Myelogenous Leukemia 
 
Since the description of BCR–ABL oncogene, a myriad of treatment options have been 
explored in CML, including arsenic trioxide, spleenic irradiation, busulphan, 
hydroxycarbamide. These compounds could only control the proliferation of white 
blood cells and enlargment of the spleen, but didn’t avoid the disease progression to 
accelerated phase and blast crisis. Most relevant results were obtained with the 
introduction of therapy with  recombinant Interferon-α (rIFN-α), which compared to 
conventional chemotherapy, is more effective, especially in patients with early chronic 
phase (13,14). The introduction of rIFN-α induced cytogenetic remission and increased 
survival (15). The exact mechanisms of action of rIFN-α have not been identified, but it 
is widely believed that they involve immune response to tumor cells, abnormal 
expression of adhesion molecules, and induction of tumor cell death (16). In spite of the 
effectiveness of rIFN-α treatment, however, there are limitations, from poor patient 
compliance to development of anti–rIFN-α antibody. The only curative approach is 
stem cell transplantation, however, as the average age of onset is >50 yrs of age, this 
factor, combined with the inability to identify suitably matched donors in all cases, 
limits this option to a minority of patients (17). The most exciting breakthrough in the 
treatment of CML has been the development of Imatinib Mesylate (IM) a selective 
kinase inhibitor, able to inhibit the activity of constitutive tyrosine kinase activity of 
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Bcr-Abl protein (18). Imatinib acts as a competitive inhibitor of ATP, it binds to the 
ATP binding site located on ABL and block the action of the tyrosine kinase in an 
irreversible way. The inhibition of kinase activity of bcr-abl inhibit neoplastic clone 
proliferation and has a significant effect on haematological and cytogenetics level. 
However, some patients with an advanced disease develop resistance to Imatinib due to 
secondary point mutations in the bcr-abl tyrosine kinase domain or due to BCR-ABL 
gene amplification (19). It has been proposed that the interaction between leukemic 
cells and the bone marrow microenvironment may play an important role in CML 
pathogenesis (20). A better understanding of the mechanisms involved in the disease 
progression may provide information to develop new treatment strategies. 
 
Chronic Myelogenous Leukemia and Angiogenesis 
 
Angiogenesis is the formation of new blood vessels from an existiting vasculature. It 
involves degradation of extracellular matrix proteins and activation, proliferation and 
migration of endothelial cells and pericytes in a multistep process (21).  Angiogenesis is 
mediated by a balance of various positive [eg vascular endothelial growth factor 
(VEGF), fibroblast growth factor-2 (FGF-2), hepatocyte growth factor (HGF), 
interleukin-8 (IL-8), transforming growth factors (TGF-α, TGF-β), matrix 
metalloproteinases (MMPs)] and negative [eg platelet factor-4 (PF-4) tissue inhibitors 
of metalloproteinases (TIMPs)] angiogenic molecules released by tumor cells (22,23). 
Tumor angiogenesis is linked to a switch in this balance, and mainly depends  on the 
release by neoplastic cells of growth factors specific for endothelial cells and able to 
stimulate the growth of the host’s blood vessels (24). This complex pathomechanism 
may comprise a direct stimulation of endothelial cells (paracrine loop) resulting in 
proliferation, sprouting and release of growth factors and on the other hand, an 
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autocrine stimulation by inhibition of apoptosis and promotion of growth (Fig. 3), 
finally leading to an expansion of the neoplastic cell clone (25,26). 
 
 
 
Recently, there are evidence that implicates angiogenesis in the growth and progression 
of CML (27). Lundberg LG et al., have found increased plasma levels of VEGF as well 
as other angiogenic factors such as FGF-2 and HGF and increased marrow vascularity 
in patients with CML (28). Bcr-Abl has also been involved in VEGF-mediated 
angiogenesis in CML and evidence indicates that the formation of new vessels plays an 
important role in the development and progression of CML. It has been proposed that 
the interaction between leukemic cells and the bone marrow microenvironment may 
play an important role in CML pathogenesis (20). An important aspect in the study of 
CML is the cross-talk between leukemic cells and bone marrow microenvironment. This 
microenvironment may facilitate tumor progression by the pertubation of CXCR4-SDF1 
Fig. 3: Dynamics of angiogenesis in hematological neoplasias: angiogenic factors secreted by 
neoplastic cells promote cell growth and inhibit apoptosis (autocrine stimulation). On the 
other side, these angiogenic mediators can also stimulate endothelial cell proliferation and 
enhance the production and release of hematopoietic growth factors (paracrine 
stimulation). 
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axis. Kalinkovich et al, have shown that microvesicles isolated from patients with 
leukaemia contain CXCR4, and these vesicles CXCR4+ are more abundant in leukemic 
patients compared to healthy individuals (29). CXCR4-SDF1 leads the increase of 
cytokines as IL8. IL8 stimulates the expression of VEGF, SDF-1 and IL6 in endothelial 
cells resulting in promoting angiogenesis. Many studies have shown over-expression of 
IL8 by tumor cells, often induced in response to chemotherapeutic interventions or 
environmental stresses such as hypoxia. The increased synthesis and secretion of IL8 
from tumor cells activate many signalling pathways through the binding of IL8 to two 
cell-surface G-protein-coupled receptors, CXCR1 and CXCR2 (30,31) in cancer cells, 
endothelial cells and neutrophils/tumor associated macrophages. Activation of IL8 
signalling pathways, through Akt, PKC and MAPK, have been detected in multiple 
forms of cancer and its role in modulating cell survival, angiogenesis and cell migration 
have estabilished this kinases as an important therapeutic target in cancer (32). As a 
consequence of the activation of these signalling pathways, IL8 may affect different cell 
types within tumor microenvironment. For example, activation of IL8 receptors on 
endothelial cells is known to promote an angiogenic response, inducing proliferation, 
survival and migration of vascular endothelial cells (33). IL8 secretion from cancer cells 
can enhance the proliferation and survival of cancer cells throug autocrine signalling 
pathway. In addition, tumor-derived IL8 will activate endothelial cells in the tumor 
vasculature to promote angiogenesis and induce a chemotactic infiltration of neutrophils 
into tumor site. It is reported also that cell adhesion molecules play an important role in 
angiogenesis. Adhesion is in part mediated by β1 integrins (VLA4 and VLA5) and 
CD44 expressed on leukemia cells, and the fibronectin and vascular cell adhesion 
molecule-1 (VCAM1), expressed on the stromal layer (34).  During new capillary 
development, coordinated signals from both integrins and growth factor receptors 
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regulate the survival, proliferation and invasion of endothelial cells.  
 
Exosomes Formation 
 
Exosomes are small, 40-100 nm, membrane vesicles of endocytic origin that are 
secreted by a variety of cell types like B-cells (35), T-cells (37), mast cells (37), DCs 
(38), platelets (39), neurons (40) and epithelial cells (41) into the extracellular space. 
They were first described as microvesicles containing 5’́-nucleotidase activity secreted 
by neoplastic cell lines (42). Few years later another group reported secretion of small 
vesicles of endocytic origin by cultured reticulocytes, and these small vesicles contained 
the transferrin receptor. Using electron microscopy (EM) they observed these vesicles in 
late endosomes, and the fusion of these late endosomes with the cell membrane resulted 
in the release of the vesicles extracellularly (43,44). In addition to cultured cells, 
exosomes have today further been isolated from a number of body fluids such as plasma 
(45), urine (46), synovial fluid (47), malignant effusions (48), epididymal fluid (49) and 
from seminal plasma, in which the vesicles are derived from prostate cells and called 
prostasomes (50). Exosomes correspond to the intraluminal vesicles (ILVs) of late 
endosomal compartments called multivesicular bodies (MVBs). These intraluminal 
vesicles are formed by inward budding of the limiting endosomal membrane and 
contain cytosol from the cell. MVBs are involved in transporting proteins for 
degradation in lysosomes. Alternatively, the MVBs can fuse with the plasma membrane 
leading to the release of the intraluminal vesicles extracellularly which are then called 
exosomes (35),(44). Proteins and lipids are sorted at the limiting membrane of 
endosomes during the formation of the intraluminal vesicles and as a consequence the 
released exosomes will contain molecules reflecting their origin from late endosomes 
(51). The mechanisms leading to exosome release are unknown. However, the 
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transmembrane protein TSAP6 has been suggested to be involved in regulating 
exosome production (52). Furthermore, Rab11, a member of the small GTPase family, 
together with calcium were shown to be important for the docking and fusion of MVBs 
with the plasma membrane (53, 54, 55) (fig. 4). 
 
 A machinery responsible for sorting proteins in intraluminal vesicles has recently been 
identified and called ESCRT (Endosomal Sorting Complex Required for Transport) 
(56). The ESCRT-0, -I and -II complexes recognize and sequester ubiquitinated proteins 
in the endosomal membrane, whereas the ESCRT-III complex seems to be responsible 
for membrane budding (57). The ESCRT proteins are required for the targeting of 
membrane for lysosomal degradation while the function of the ESCRT machinary in the 
formation of ILVs that are further secreted as exosomes is not clear.  Proteomic analysis 
of purified exosomes from different sources show an enrichment of ESCRT components 
and ubiquitinated proteins (58, 59). The expression of the Nedd4 family interacting-
protein1, that is associated with elevated levels of protein ubiquitination in exosomes 
(60), and Alix, a protein associated with ESCRT machinary, is required for the sorting 
Fig. 4: Mechanism of exosomes release 
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of the transferrin receptor into exosomes (61). This leads to the hypothesis that ESCRT 
could be required for exosomal cargo. Lipid rafts has also been suggested to be involved 
in protein sorting into intraluminal vesicles (62) and typical raft components has been 
identified on exosomes such as glycolipids, Src tyrosine kinases and cholesterol (62,63). 
How MVBs discriminate between proteins that are destined for exosomal secretion or 
lysosomal degradation remains to be determined. In APC, MHC class II are 
accumulated in MVBs which are called MIICs. These MIICs are the major site for 
peptide loading, and subsequently exosomes from APC bear peptide-loaded MHC on 
their surface. 
 
Exosome composition 
 
Physical properties and purification of exosomes 
 
The common procedure to purify exosomes from cell culture supernatants involves a 
series of centrifugations to remove cells and cell debris. Filtration of the cell-culture 
supernatant through 0.22-µm filters, followed by direct high-speed ultracentrifugation 
(64), reduces the contamination of exosome preparations with larger vesicles that are 
shed from the plasma membrane.  In addition, because exosomes are present in serum it 
is crucial to avoid contamination with bovine exosomes from the fetal calf serum (FCS) 
that is used to culture the exosome-producing cells (65). For this reason, serum for 
culture medium can be depleted from serum exosomes by overnight high speed 
ultracentrifugation (65,36). To be sure that the isolated vesicles are exosomes must be 
used other criteria to identify exosomes. Exosomes float on sucrose gradients, and their 
density ranges from 1.13 g ml-1 to 1.19 g ml-1 (66). Contaminating material, such as 
protein aggregates or nucleosomal fragments that are released by apoptotic cells, are 
separated from exosomes by flotation on sucrose gradient (64). Electron microscopy is 
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also used to recognized exosomes by revealing the characteristic “cup-shaped” 
morphology, a flattened sphere limited by a lipid by-layer (67). These characteristics are 
consistent with the observed size and morphology of internal vesicles in multivesicular 
endosomes (68). 
Molecular composition of exosomes 
 
The molecular composition of exosomes depending on the cell from which they are 
secreted and their endosomal origin. Immuno-Electron Microscopy localization studies, 
Western blot analysis and peptide mass mapping of exosomal proteins from Dendritic 
Cells (DCs) (64,65), B lymphocytes (68,69), intestinal epithelial cells (41), and other 
cell types revealed the presence of common as well as cell-type-specific proteins. For 
example, exosomes from DCs, mast cells and B cells are enriched in MHC class I and 
MHC class II and  express co-stimulatory molecules like CD54 (also called ICAM-1), 
CD80 and CD86 (66,69),  exosomes from T cells bear CD3 (36) and exosomes from 
cytotoxic T cell contain perforin and granzymes (70), exosomes from reticulocytes 
contain the transferrin receptor (71). In addition to cell-specific molecules, exosomes 
also contain common components (Fig. 5) 
 
Fig. 5: Common molecular components of exosomes. 
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They are enriched in a family of proteins called tetraspanin which are cell-surface 
proteins that span the membrane four times (69). Tetraspanin proteins are found on the 
surface of many cell types but also in endosomal compartments. Tetraspanins form 
complexes by interacting between themselves as well as with a large variety of 
transmembrane and cytosolic proteins (72). These tetraspanin complexes are located in 
microdomains, termed TEM domains (tetraspanin-enriched membrane domains) (73). 
TEM domains are different from rafts and clathrin-coated pits, but share with these 
structures a specific capacity to facilitate vesicular fusion and/or fission (74,75). 
Tetraspanins act as ‘molecular facilitators’, which modulate, stabilize or prevent 
activities of associated molecules (76). They promote spreading, migration and cable 
formation by adjusting integrin compartmentalization, internalization, recycling and 
signalling (77). By regulating protein traffic, tetraspanins become involved in cell 
adhesion (78), and by modulating biosynthesis of associated molecules, such as MMPs 
(matrixmetalloproteinases), they may influence invasiveness (79). The main functions 
are cellular motility, invasion and fusion (80). Examples of tetraspanin proteins found 
on exosomes are CD9, CD63 and CD81. Exosomes have also been demonstrated to 
contain heat shock proteins (Hsps) like Hsp70, Hsc70, Hsc73 and Hsp90 (81,65). Heat 
shock proteins are a family of proteins which act as chaperones to facilitate the folding 
of protein intracellularly. Hsps can also be secreted and have extracellular functions 
such as immuno-regulatory activities. Hsps can be both constitutively expressed and be 
induced by cellular stress. Heat stressed cells have been shown to increase the 
expression of Hsps on their released exosomes (81). These ubiquitous proteins are 
involved in antigen presentation, as they can bind antigenic peptides and participate in 
loading peptides onto MHC molecules (82). MHC class I molecules are also present in 
exosomes from most cell types. Moreover, exosomes contain cytoskeleton proteins like 
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actin, tubulin and moesin, ESCRT proteins like Tsg101 and alix and proteins involved in 
intracellular membrane fusions and transports and fusion like Rab proteins and annexins 
(64,83). They also include molecules that are involved in  signal transduction (such as 
protein kinases, 14-3-3 and heterotrimeric G proteins) and various metabolic enzymes 
(such as peroxidases, pyruvate and lipid kinases, and enolase-1). Furthermore, 
exosomes express CD55 and CD59 which have been shown to protect them from 
complement lysis (84) suggesting them to be stable in vivo. Exosomes also contain 
proteins that are involved in specific cell functions. Exosomes from antigen-presenting 
cells (APCs) have been analysed in most detail. MHC class II molecules are very 
abundant in exosomes from all cells that express MHC class II. Exosomes from DCs 
also contain CD86, which is an important co-stimulatory molecule for T cells. T-cell 
receptors are also specifically enriched on T-cell-derived exosomes. Exosomes contain a 
series of cell-specific transmembrane proteins including α- and β-chains of integrins 
(such as αM on DCs, β2 on DCs and T cells, and α4β1 on reticulocytes), 
immunoglobulin-family members (such as intercellularadhesion molecule 1 
(ICAM1)/CD54 on B cells, A33 antigen on enterocytes and P-selectin on platelets) or 
cell-surface peptidases (such as dipeptidylpeptidase IV/CD26 on enterocytes and 
aminopeptidase N/CD13on mastocytes). 
Milk-fat-globule EGF-factor VIII(MFGE8)/lactadherin (85), a milk-fat-globule protein 
that is expressed by DCs and some tumour-cell lines, was found very abundant in 
exosomes that are produced by these cells (65). These proteins probably ‘address’ 
exosomes to target cells. 
 
Exosome function 
 
Exosomes have been suggested to participate in different physiological and/or 
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pathological processes within the extracellular space and in biological fluids (e.g. urine, 
serum,) (86,87,88). Exosomes functionality seems to be determined by cell-type 
specific proteins that reflect the specialized function of their original cells. When 
exosomes were initially discovered from reticulocytes, they were shown to function as a 
way of removing unnecessary proteins such as the transferrin receptor during the 
maturation process of reticulocytes into erythrocytes (89). Another function of 
exosomes that was later described is as cell free messengers, which can be released 
from one cell and have an effect on another one. This communication with other cells 
may occur either in the microenvironment, or over a distance (90). Since exosomes have 
been found in blood plasma (45), they may be transported between organs via the 
systemic circulation. How this interaction occurs between exosomes and cells is not 
fully known. However, several mechanisms describing the interactions of exosomes and 
cells have been hypothesized. Exosomes can bind to cells through receptor-ligand 
interactions, similar to cell to cell communication, mediating for example antigen 
presentation (35,91). Clayton et al. showed that B cell exosomes express functional 
integrins, which are capable of mediating adhesion to extracellular matrix components 
and activated fibroblasts. This adhesion was strong and resulted in an increase in 
intracellular calcium concentration (92). Alternatively, exosomes can attach to or fuse 
with the target cell membrane, thus delivering exosomal surface proteins and perhaps 
cytoplasm to the recipient cell (93). MHCII positive exosomes have been shown to be 
attached to follicular DCs. These cells do not express MHCII themselves, and the 
exosomes provide them with new properties (93). Finally, exosomes may be 
internalized by the recipient cells due to mechanisms such as endocytosis. Immature 
DCs have been shown to internalize and process exosomes for antigen presentation to 
CD4+ T cells (94). Later this was also shown for the integrin α4β1 which was down 
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regulated from the red blood cell surface and instead found on the surface of released 
exosomes, and in addition this made the exosomes able to bind to fibrinonectin (95). 
Through their ability to bind target cells, they are likely to modulate selected cellular 
activities such as vascular homeostasis, and participate in the signaling events 
contributing to antigen presentation to T cells (35) and the development of tolerance 
(96). 
 
Exosomes in Cancer 
 
Cancer cells begin to mould their stromal environment starting at early phases of the 
neoplastic process mainly by pathways involving cell-to-cell contact and the release of  
soluble factors, as TNFα, TGFβ, VEGF, that are able to influence the recruitment of 
different cell types (e.g. myeloid cells, hematopoietic progenitors cells). Recently, an 
alternative novel mechanism involves the active release by tumor cells of exosomes. 
Tumor exosomes, seem to have dual functions with completely opposite effects, either 
they can activate or suppress immune response against cancer.  
 
Protumorigenic role of tumor-derived exosomes  
 
Tumor-derived exosomes have been implicated in facilitating tumor invasion and 
metastasis. By stimulating angiogenesis, modulating factors released by stromal cells, 
and remodelling extracellular matrix, tumor-derived exosomes have been found to 
contribute to the establishment of a premetastatic niche, generating a suitable 
microenvironment in distant metastatic sites (97). Exosomes can increase extracellular 
matrix degradation and augment tumor invasion into the stroma (98,99). It was 
suggested that CD44 is required for the assembly of a soluble matrix that, in 
cooperation with exosomes, promotes leukocyte, stroma, and endothelial cell activation 
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in the (pre)metastatic organ. Tumor-derived exosomes may also transport apoptosis 
inhibitory proteins, induced under stress conditions, to promote tumor survival. For 
example, survivin, a member of the inhibitor of apoptosis protein family, can be 
absorbed by cancer cells from extracellular media and inhibit their apoptosis following 
genotoxic stress as well as increase their replicative and metastatic ability (100). 
Another pronounced effect of tumor-derived exosomes is their ability to modulate the 
function of stromal cells such as fibroblasts. It was recently shown that exosomes shed 
by prostate, colorectal and breast cancer cells lines contain TGF-β on their surface in 
association with betaglycan and can trigger SMAD-dependent signaling. Exosomal 
delivery of TGF-β is capable of driving the differentiation of fibroblasts into 
myofibroblasts, whose enrichment in solid tumor represents an altered stroma that 
supports tumor growth, vascularization, and metastasis (101). These observations 
suggest a protumorigenic role of tumor-exosomal TGF-β in addition to their 
immunosuppressive functions. However, it was also noted that TGF-β is not universally 
present on exosomes derived from all cancer cells. Tumor-derived exosomes were 
shown to directly suppress the activity of effector T cells. Exosomes from melanoma 
and colorectal cancer cells express death ligand such as FasL and TRAIL, both of which 
can trigger the apoptotic death of activated T cells (102,103). Furthermore, ovarian 
tumor derived exosomes are able to down-modulate CD3-ζ chain expression and impair 
TCR signaling (103,104), suggesting that tumor-derived exosomes can also 
downregulate T cell function in addition to direct killing. In addition, NKG2D 
dependent cytotoxicity of NK cells and CD8+ T cells was inhibited by NKG2D ligand-
containing exosomes derived from human breast cancer and mesothelioma cell lines 
(105,106). Similarly, murine mammary carcinoma exosomes were shown to promote 
tumor growth in vivo by suppressing NK cell function (107). These observations 
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suggest that tumor-derived exosomes can negatively regulate immune system, in 
particular T cells and NK cells. In addition, tumor-derived exosomes can also support 
the function of regulatory T (Treg) cells. Mesothelioma and prostate-derived exosomes 
were found to selectively impair the IL-2 response to cytotoxic effector cells while 
supporting Treg cell activities through a TGF-β-dependent mechanism (108). Exosomes 
from sera of patients with head and neck cancer were also reported to induce, expand, 
and upregulate the suppressor functions of human Treg cells as well as enhance their 
resistance to apoptosis via a TGF-β- and IL-10-dependent mechanism (109) (Fig. 6)  
 
 
Fig. 6: The protumorigenic role of tumor-derived exosomes 
 
Another mechanism that have a role in cell-cell communication within the tumor 
microenvironment is the intercellular exchange of proteins and genetic materials via 
exosomes (110). In particular, transport of mRNAs and microRNAs, from tumor cells to 
neighboring cells could have significant effects on tumorigenesis. It has been suggested 
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that the ability of exosomes to deliver nucleic acids to distal cells also makes them ideal 
candidates for gene therapy (111). 
 
Antitumorigenic role of tumor-derived exosomes 
 
Immune responses can be triggered by tumor-derived exosomes that contain tumor-
specific antigens and peptide-MHC complexes. Antigens that are commonly present in 
tumour-derived exosomes include melan-A (112), carcinoembryonic antigen (CEA) 
(113), and mesothelin (108). Immunization of mice with Dendritic cells (DCs) pulsed 
with cancer cell–derived exosomes demonstrate that it is possible to induce protective 
antitumour immune responses using cancer-derived exosomes as a source of antigens 
(114). Similarly, in an ex vivo human model system, exosomes taken from malignant 
effusions proved an effective source of tumour antigens for cross-presentation to CD8+ 
cytotoxic T cells by DCs (112). Expression of heat shock proteins (such as Hsp70) at the 
exosome surface is important, not only as a cofactor for efficient receptor-mediated 
uptake, but also for “danger” signals that trigger DC maturation and that subsequently 
enhance immunologic activation. Thus, exposing cancer cells to stress may render their 
exosomes significantly more immunogenic (115). DC have an active role in processing 
and cross-presenting exosomally delivered antigens, but this immune function depends 
from cancer exosomes phenotype and the influence of the microenvironment. Exosomes 
are able to activate also monocytes to secrete pro-inflammatory cytokines (116) and 
activate B cells through CD40L, thereby bypassing the need for CD4+ T cell help (117). 
Recently, ligands for NK cell-activating receptors on exosomes derived from immature 
human DCs were shown to promote NK cell activation in vitro. This occured through 
UL16 binding protein 1, MHC class I polypeptide-related sequence A (MICA) and 
MICB (which are ligands for NKG2D) on exosomes secreted by DCs from healthy 
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volunteers or patients with melanoma (118). The ability of these exosomes to activate 
NK cells was apparently due to the simultaneous presence of the IL-15 receptor α-chain 
(Il-15Rα) on the DC-derived exosomes, which could bind to exogenous Il-15 and 
thereby promote NK cell proliferation (119). 
In addition to the potential immunostimularoty effects, a proapoptotic function of 
tumor-derived exosomes directly on tumor cells was also reported. Exosomes  from 
human pancreatic tumor cells were reported to increase Bax and decrease Bcl-2 
expression, inducing tumor cells toward apoptotic pathway (120). 
 
Exosomes and Angiogenesis 
 
It has been showed that exosomes are able to alter microenvironment through their 
protein content. Tumor derived exosomes can contribute to establish an oncogenic niche 
via delivery of protein, mRNA and miRNA that support angiogenesis, cell proliferation 
and cell survival (Fig. 7).  
 
Fig. 7: Exosomes alter microenvironment and recipient cells. Exosomes help to establish a 
metastatic niche to aid tumor growth and tumor metastatis. 
 
 
Tumor derived exosomes contain several cytokines and growth factors such as tumor 
necrosis factor TNF-α, IL-1β, and TGF-β as well as functional receptors like TNFR1 
and TfR2 and through these molecules enhance recruitment of hematopoietic and 
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endothelial precursor cells to enhance neoangiogenesis in the tumor (121). Proteomic 
analysis of mesothelioma cell-derived exosomes, detected the presence of angiogenic 
factors that can increase vascular development in tumor microenvironment (122). Hood 
et al, showed that melanoma-derived exosomes stimulated endothelial signalling 
important for tissue matrix remodelling and endothelial angiogenesis (123). Recent 
studies showed that pancreatic tumour-derived exosomes increase matrix 
metalloproteinase (MMP) secretion and VEGF expression in target cells through the 
expression of proangiogenic molecules, such as members of the Tetraspanin family, thus 
promoting neo-angiogenesis even at tumour distant sites (124).  Tetraspanins, which are 
constitutively enriched in exosomes, have been found to contribute to exosome-
mediated angiogenesis. It was reported that exosomes derived from a pancreatic tumor 
line over-expressing D6.1A,  strongly induced endothelial cell branching in vitro and 
angiogenesis in vivo in a rat model (124). Tumor derived D6.1A stimulates the secretion 
of matrix metalloproteinase and urokinase-type plasminogen activator, enhances the 
expression of vascular endothelial growth factor expression in fibroblasts, and 
upregulates the expression of endothelial growth factor receptor. Exosomal Tspan8 
(D6.1A) was found to contribute to the selective recruitment of proteins and mRNA into 
exosomes, including CD106 and CD49d, both of which were implicated in the binding 
and internalization of exosomes by endothelial cells. Induction of several angiogenesis-
related genes, including von Willebrand factor, Tspan8, chemokines CXCL5 (C-X-C 
motif chemokine 5), MIF (macrophage migration inhibitory factor), chemokine receptor 
CCR1, together with enhanced endothelial cell proliferation, migration sprouting and 
maturation of endothelial cell progenitors, were seen upon exosome internalisation 
(125). Circulating exosomes obtained from plasma of glioma patients were positive for 
the mutant/variant mRNA of epidermal growth factor receptor (EGFRvIII), which 
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defines a clinical subtype of glioma. Interestingly, these exosomes display 
proangiogenic properties, indicating that glioma derived exosomes play a role in 
initiating angiogenesis (126). Skog et al, showed that these exosomes mediate transfer 
of mRNA. Transfer of mRNA can modify the translational profile of these cells and 
promote acquisition of the angiogenic  phenotype. Nevertheless, those particles also 
contain growth factors and proteases and have been shown to stimulate tubule formation 
in endothelial cells (126). Recently, it has been shown that Delta-like ligand 4, a 
transmembrane ligand for the Notch family of receptors, is incorporated in exosomes. 
Notch signaling is a cell-cell signaling pathway that have a role in several biologic 
processes, such as cell fate determination and differentiation (127), and also it is 
implicated in vascular development and angiogenesis (128). Delta-like 4 (Dll4) 
expression is particularly critical for angiogenesis (129), and its expression is restricted 
to the endothelium of developing vessels and regulate the vessel sprouting and 
branching (128). Exosomes that have Dll4 can transfer this protein from one cell type to 
another and incorporate it into the plasma membrane in vitro and in vivo. Dll4-
containing exosomes increases capillary-like structure formation in vitro and in vivo by 
a mechanism that implicates the transfer of Delta-like-4 into the endothelium. This 
suggests that Delta like/Notch pathway does not require direct cell–cell contact to 
expand its signaling potential on angiogenesis (130). Taraboletti et al, have shown that 
matrix metalloproteinases contained in exosomes released from endothelial cells are 
functionally active and lead to endothelial cell invasion and capillary-like formation 
(131). Owing to the multifunctional protein repertoire transported by tumour exosomes, 
it could be hypothesized that they may also contribute to the process of stromal 
remodelling, thus widening the role of these microvesicles in tumour progression and 
metastasis formation. Exosomes are critical for some pathological disease processes, 
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then find a strategy of targeting the formation and/or release of exosomes in specific cell 
types, would represent a novel route of therapeutic intervention. 
 
Exosomes as biomarkers 
 
Exosomes have been shown in physiological and pathological fluids such as 
bronchoalveolar lavage (132), human plasma (45), malignant and pleural effusions 
(48,133), urine  (46), breast milk  (134), human saliva (135), synovial fluid (136) and 
malignant ovarian ascites. The presence of these bioactive vesicles in plasma and 
malignant effusions of patients with cancer (48) suggests that exosomes may lead to 
potential diagnostic biomarkers of disease conditions and play an important role in 
cancer diagnosis. Most cancers, such as ovarian cancer, are diagnosed at advanced stage 
and prospects for significant improvement in survival reside in early diagnosis then it is 
necessary to find non-invasive cancer biomarkers to detect cancer in its early stages. 
Currently, effective screening protocols are not available, because the classical 
biomarkers, for example  CA125 for ovarian cancer, is thought to be robust only in 
following the response or progression of the disease, but not as a diagnostic or 
prognostic marker (137). Thus, it is important to identify additional diagnostic and 
prognostic markers for this disease. The increased levels of plasma-exosome in patients 
with advanced disease [e.g., mean 2.85 mg/mL exosomes for lung cancer 
adenocarcinoma patients compared with 0.77 mg/mL exosomes in the blood of normal 
volunteers (138)] and the discovery of cancer miRNA profiles in circulating plasma-
derived exosome, giving exosomes an attractive biomarker candidate. Because 
exosomes transport molecules involved in cancer progression they can be used as 
markers, for example in exosomes may be present cancer-associated antigens not 
available as soluble molecules within biological fluids, such as the oncofetal 
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glycoprotein-5T4; which is over expressed by epithelial cancers but not shed from the 
cell surface (139). In a recent study, prostate cancer biomarkers, PCA-3 and TMPRSS2; 
ERG, were detected in exosomes isolated from the urine of prostate cancer patients 
(140), and they have been proposed  as a possible source of multiple biomarkers of 
renal  disease (46,141) and urological cancer. Exosomes are also an attractive biomarker 
candidate for bladder cancer. The differentially expressed proteins include psoriasin, 
kertain-14, galectin-7, epidermal fatty acid binding protein (E-FABP), migration 
inhibitor factor-related protein (MRP8) and stratifin, which may be useful markers for 
the diagnosis of bladder cancer (46). 
In the past years, the importance of  miRNA in cancer cells has been recognized. 
MicroRNAs, small (22–25 nucleotides in length) noncoding RNAs, suppress the 
translation of target mRNAs by binding to their 3′ untranslated region (142,143). Post-
transcriptional silencing of target genes by microRNA can occur either by cleavage of 
homologous mRNA or by specific inhibition of protein synthesis. A correct control of 
miRNA expression is essential for cellular processes, such as proliferation, 
differentation, development and cell death. Valadi et al. reported the presence of mRNA 
and miRNA in exosomes from mouse and human mast cell lines. Exosomes are able to 
transport biologically mRNA and miRNA to neighboring cells that confer new functions 
to the recipient cells (111). These studies highlight the potential of exosomal microRNA 
profiles for use as diagnostic biomarkers of disease through a non invasive blood test. 
The expressions of individual microRNAs and specific microRNA signatures have now 
been linked to the diagnosis and prognosis of many human cancers. A possible obstacle 
in body fluid based exosome analysis is the presence of contaminating exosomes 
secreted by normal cells (e.g., normal ovarian cells as compared to ovarian cancer 
cells). To discriminate two population of exosomes can be used specific purification 
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strategy, as a magnetic bead immune capture technique was employed to isolate 
circulating epithelial cell adhesion molecule-positive exosomes from the plasma of 
ovarian cancer and lung cancer (Fig. ). 
 
Fig. 8: Circulating exosomes can be a rich source for identifying potential biomarkers. Patient 
plasma contains exosomes that are released by disease cells (e.g., colorectal cancer cells), normal 
counterpart (e.g., normal colon cells) and other normal cells (e.g., liver). Exosomal tissue signatures 
can be used to isolate disease cell-derived exosomes for proteomic and transcriptomic profiling. 
 
Currently, a major goal is to identify disease biomarkers in biological fluids, in a non-
invasive manner, that can be measured relatively inexpensively for early diagnosis of 
disease and treatment success. 
Exosomes in Immunotherapy 
 
The first antitumor effects of exosomes was demonstrated by Zitvogel et al, they 
showed that exosomes from DCs pulsed  with tumor peptides could prime a specific 
cytotoxic T lymphocyte (CTLs) in vivo and suppress growth of established tumors when 
injected into mice (38,144). Particularly in combination with TLR 3 and 9 ligands, 
exosomes efficiently induced anti-tumor responses in mice (145). These promising 
 26
results in mice led to the development of techniques for the clinical testing of tumor 
antigen loaded DC exosomes in human advanced cancer patients (66). 
When dendritic cells are pulsed with cancer antigens or tumor peptides (38) dendritic 
cell-derived exosomes (DEX) has been shown to elicit stronger immune responses 
toward cancer cells (146) with up-regulation of specific antibody release and cytokine 
production (147). Furthermore, it has also been reported that DEX trigger NK cells in 
the immune response toward cancer cells via NKG2D-dependent NK cell activation and 
IL-15Rα-dependent cell proliferation (119). 
Some clinical trials have been performed in humans with advanced staged melanoma 
and non small cell lung cancer. Patients were treated with tumor peptide loaded DC 
exosomes and the outcome was promising. The treatment was well tolerated and some 
patients showed long term stability of the disease (148,149) (Fig. 9).  
 
Fig. 9: Clinical grade exosomes in immunotherapy. The process of how DEX can be derived, 
purified, and utilized in cancer treatment. Creative Commons. Reproduced with permission from 
Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous 
dendritic cell (DC) derived-exosomes: results of the first phase I clinical trial. J Transl Med. 
2005;3(1):10. 
 
Although it has been established from the results in clinical  trials that exosomes can be 
safely administered, it is necessary to increase their potency to elicit appropriate 
immune A phase II clinical trial is planned to follow-up the initial positive results (150).  
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responses to kill cancer cells. Different strategies have been applied to increase the 
immunogenicity of exosomes, for example the addition of adjuvant such as double 
stranded RNA or CpG (150). Another strategy that has been tested is the modulation of 
the exosome composition. Exosomes from mature DC have been shown to be more 
immunogenic than those from immature DC (151). Recent evidence suggests that a new 
strategy is represented by artificially coating and engineering exosomes (152) with 
tumor antigens to make it more recognizable to the immune system. It has been 
experimentally demonstrated that using nanotechnology, exosomes can be engineered to 
bear an optimal number of MHC I and ligands that would activate T cells, and their in 
vivo activity can be traced by encapsulating superparamagnetic iron oxide nanoparticles 
(153). Exosomes can also carry cytokines, DNA, RNA, adjuvants, labels, costimulatory 
signals, and gene therapy vectors, which makes it ideal to develop new immunotherapy 
strategies. 
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Immune system and tumor 
 
The immune system is essential in tumor progression modulation and elimination of 
cancer cells. Immune cells, from both the innate and adaptive immune systems, are able 
to recognize, attack, and kill tumor cells in various ways. They collaborate and stimulate 
each other (e.g. with IFN-γ) to induce a potent immune response against the tumor cells. 
However, cancer still occurs. Tumor cells are able to fight back or hide from the 
immune system. The interaction between tumor and immune system consist of three 
phases and is known as cancer immunoediting (154). During the first phase (the 
elimination or cancer immunosurveillance phase) the immune system is able to protect 
the host from a developing tumor. However, some transformed cells may escape the 
immunological pressure, thereby entering the second phase (the equilibrium phase). 
During this period of immune-mediated latency, the tumor persists and acquires new 
mutations. This may allow the tumor to enter the third phase (tumor escape) during 
which established tumors become clinically manifest (155). 
The innate immune system provides the first line of immediate defense and includes 
natural killer (NK) cells, γδ T cells, monocytes, macrophages, neutrophils and dendritic 
cells. NK cells are able to discriminate between self and non-self. The first activating 
signal for NK cells is a loss of MHC class I molecules on the surface of cancer cells 
(156). MHC class I molecules act as an inhibitory signal for NK cells, thus making 
MHC class I lacking tumor cells a target for NK cells. NK cells use their large repertoire 
of inhibitory and activating receptors to detect the transformed-self. Many tumor cells 
express activating NK ligands (like MICA and MICB) recognized by NKG2D and are 
thus efficiently eliminated by NK cells and γδ T cells (157). Tumors express antigens 
that are recognized as foreign by the immune system of the tumor-bearing host. The 
immunogenicity of tumors implies that tumor cells express antigens that are recognized 
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as foreign by the adaptive immune system. These tumor antigens, presented on the 
surface of antigen presenting cell (APCs), are recognized by T lymphocytes cells and 
leading to a tumor specific reaction. To mount an adaptive immune response, two 
signals are mandatory. The first signal is provided by the presentation of an antigen in 
the groove of an MHC molecule to the T cell receptor (TCR).The second signal is 
provided by the ligation of co-stimulatory molecules (the most important being CD28 
on T cells interacting with CD80 and CD86 on the APCs (158). These two signals 
activate the adaptive system to recognize and kill tumor cells. After successful 
recognition of the tumor cell by innate and adaptive effector cells, cytotoxic T 
lymphocytes, γδ T cells and NK cells both utilise a pore-forming protein, perforin, and a 
battery of serine proteases (granzymes) that activate caspases, leading to apoptosis. The 
apoptotic program can also be activated after binding of TRAIL or Fas-ligand, 
expressed on the cell surface of the effector cell, to one of its cognate receptors. These 
lymphocytes are able to kill tumor cells via cytokines, such as IFNγ, TNFα and TNFβ. 
Tumor cells have developed numerous strategies to change their phenotype and mislead 
the immune system. Tumor cells can change their cell surface phenotype to prevent 
recognition and binding by immune effector cells. The most wellknown example of this 
strategy is the downregulation of MHC class I molecules (or molecules involved in 
antigen processing by MHC class I molecules) resulting in defective binding to the TCR 
of cytotoxic CD8+ T cells (159,160). However, downregulation of MHC class I renders 
cells susceptible for NK cell mediated killing. Consequently, tumor cells have also 
developed mechanisms to escape from NK surveillance: for example upregulation of the 
NK inhibitory HLA-G3 (161). Other strategies are the down-modulation of co-
stimulatory molecules or upregulation of pro-apoptotic molecules like FAS-ligand on 
their cell surface to induce apoptosis of effector cells (162). Another strategy is to 
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prevent the pro-apoptotic signals after effective recognition and binding of immune 
cells. An example of this evasion of immune mediated killing is to downregulate 
proapoptotic death receptors or to upregulate anti-apoptotic or decoy receptors (for 
example TRAIL-R3). Over-expression of anti-apoptotic proteins, like XIAP (X-linked 
inhibitor of apoptosis) (163,164) or molecules that block the granzyme B/perforin 
pathway like (pI-9)(165) are other examples. The third way, is to produce immune 
suppressive factors that inhibit T cell function and lead to a local state of tolerance and 
anergy. Examples of this strategy are the production of transforming growth factor beta 
(TGF-β)(166), or indoleamine 2,3-dioxygenase (IDO)(167) or IL-10.  
Recently, mounting evidence is indeed pointing to exosomes as major participants in 
immune evasion with several mechanisms. Among the earliest reports there is a 
description of melanoma-derived exosomes that were lethal to T cells (102). These 
cancer cells naturally express Fas ligand, and may expel by the multivesicular 
endosomal route at least a proportion of this molecule in exosomes. FasL–bearing 
exosomes, upon encountering activated (Fas-positive) T cells, can essentially crosslink 
T cell Fas and trigger apoptotic death (102). Other influences of exosomally expressed 
members of the tumour necrosis factor superfamily may include downmodulation by 
ovarian cancer exosomes of the CD3-ζ chain. This molecule is an integral component of 
the TCR complex, which is essential for competent signalling after TCR–MHC–peptide 
interactions (168). Melanoma exosomes expressing TNF-α may also affect the CD3–
TCR complex in a reactive oxygen species–mediated manner (169). Thus, cancer 
exosomes can exert drastic effects on T-cell functions and may constitute an important 
mechanism by which tumours eliminate activated T cells that may recognize and kill 
them (102). Other death-independent effects of cancer exosomes on the immune system 
have been reported. Liu et al., for example, pretreated mice with breast cancer 
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exosomes before implanting tumours and documented accelerated tumour growth (170). 
This accelerated growth was result of the negative influence of cancer exosomes on NK 
cell functions, inhibiting NK cell proliferation and impairing cytotoxic functions. Other 
studies showed that exosomes from cervical cancer harbor NKG2D ligand such as 
MICA*008 or ULBP3 proteins, which suppress Natural Killer cell toxicity (171).  
Thus, tumor exosomes bearing NKG2D ligands can act on effector cells to down 
regulate NKG2D, impairing part of the immune response (106). In addition to NKG2D 
ligands, it was shown that tumor exosomes carry and express growth factors such as 
TGFβ1. Membrane-bound TGFβ1 on these vesicles displays the same function as 
NKG2D ligands i.e. the down regulation of surface NKG2D expression by NK cells and 
CD8+T cells following a direct interaction between exosomes and cells. Tumor-derived 
exosomes promote other immune escape mechanisms by triggering myeloid suppressive 
cells proliferation (MDSC). These cells are found in large number in lymphoid organs, 
blood and tumor tissues in cancer patients and are immature myeloid cells. These cells 
express myeloid marker stimulatory molecules (CD14 and CD11b) and are devoid of 
co-stimulatory molecules (HLA DR, CD80, CD86). They spontaneously secret TGFβ 
and have suppressive activity on activated T lymphocytes since they are able to inhibit T 
cells proliferation and cytolytic functions (172). It was shown that melanoma and 
colorectal carcinoma derived exosomes altered the monocyte differentiation into 
dendritic cells, leading to the generation of myeloid suppressive cells (172). 
Furthermore, it was demonstrated that MDSC-mediated promotion of tumor progression 
was dependent on TGF-β present on exosomes, but also depended upon the lipidic 
mediator prostaglandin E2 (PGE2) transported by tumor exosomes (173) (Fig. 10). 
These pleiotropic effects lead to hypothesize that interfering with exosome release by 
tumour cells may perhaps represent a novel strategy for simultaneously recovering 
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multiple immune functions in cancer patients, then the knowledge on the immune 
evasion mechanism exosomes-mediated could help for developing a successful, multi-
level and multi-target anti-cancer therapy. 
 
 
 
Fig. 10: Inhibitory functions of exosomes derived from tumor cells. Inhibition of T cell activation, 
inhibition of NK cell and CD8+ T cell cytotoxicity, promotion of regulatory T cell activity, inhibition 
of monocyte differentiation into DCs and promotion of monocyte differentiation into myeloid-
derived suppressor cells (MDSCs), T cell killing through ligation of CD95 by CD95 ligand (CD95L)  
 
 
γδ T cells 
 
γδ T cells are innate effector cells able to act as firs-line defense against tumors and 
infections, but also to enhance antigen-specific immune responses mediated by 
conventional T cells and antibodies. They account for 5–10% of CD3+ peripheral blood 
T cells but constitute a dominant T-cell fraction at other anatomical sites such as the 
intestinal epithelia. γδ T cells differ from conventional αβ T cells in several aspects. αβ 
T cells are “conventional” T cells with a T cell receptor (TCR) composed of the higly 
variable α and β chains. They comprise two subpopulations CD4+ and CD8+ T cells 
and their activation depends on the interaction with professional APCs, such as dendritic 
 33
cells. γδ T cells are “unconventional” T cells that express a TCR composed of the δ and 
γ chains. Most γδ T cells lack CD4 or CD8 antigens and hence display a "double-
negative" phenotype, although a sizeable fraction expresses CD8 (174). The absence of 
CD4 or CD8 expression on the majority of circulating γδ T cells is well in line with the 
lack of MHC restriction in antigen recognition of this T-cell subset. γδT cells often show 
tissue specific localization of oligoclonal subpopulations sharing the same TCR chains 
(175). For instance, murine skin γδ T cells, so-called dendritic epidermal T cells 
(DETCs), are largely Vγ5/Vδ1+ while in the human peripheral blood, the majority of γδ 
T cells express a TCR composed of Vγ9 and the Vδ2 chains (Vγ9/Vδ2 T cells). Similar 
to αβ T cells, Vγ9Vδ2 T lymphocytes comprise distinct populations distinguishable on 
the basis of surface markers, effector functions and trafficking properties. Naive (Tnaive, 
CD45RA+CD27+) and central memory (TCM, CD45RA–CD27+) cells home to 
secondary lymphoid organs and lack immediate effector functions, whereas the so-
called effector-memory (TEM, CD45RA–CD27–) and terminally differentiated (TEMRA, 
CD45RA+CD27–) cells home to sites of inflammation where they display immediate 
effector functions such as cytokine production and cytotoxicity (176,177). Vγ9/Vδ2 T 
cells recognize through their TCR a set of non-peptidic small molecular compounds in 
an MHC-independent manner. This interaction is sufficient for their activation and does 
not require interaction with professional APC. γδ TCR enables them to recognize 
families of unprocessed nonpeptide compounds of low molecular weight (100-600 Da) 
with conserved patterns, comprising natural phosphoesters derived from mycobacteria 
and other pathogens, referred to as phosphoantigens, and to a lesser extent several 
ubiquitous metabolites such as alkylamines from plant extracts, xylosyl-or ribosyl-1-
phosphate, 2,3-diphosphoglycerate and several synthetic aminobisphosphonates 
(NBPs)(178,179,180,181).  The most potent Vγ9/Vδ2 T cell ligand, (E)-4-hydroxy-3-
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methyl-but-2-enyl pyrophosphate (HMB-PP) is an intermediate metabolite of the 
microbial non-mevalonate pathway (MEP) of isoprenoid biosynthesis (182,183). 
Through this particular specificity for microbial molecules, Vγ9/Vδ2 T cells display an 
anti-microbial immune response (184). After their activation, Vγ9/Vδ2 T cells expand 
rapidly and secrete different proinflammatory cytokines. These cytokines mediate the 
activity of other immune cells to eliminate the microbe, such as interferon-γ (IFN-γ) 
increasing the microbial degradation in macrophages lysosomes. Activated Vγ9/Vδ2 T 
cells also recognize infected cells and induce their cell death through the secretion of 
apoptosis-inducing factors such as perforin, granzyme and tumour necrosis factor-
related apoptosis-inducing ligand (TRAIL). Fas-ligand expressed on Vγ9/Vδ2 T cell 
membrane can also directly interact with its receptor Fas on target cells and induce 
apoptosis. γδ T cells also recognize metabolites of the mevalonate pathway of the 
isoprenoid biosynthesis, present in all eukaryotic cells. Isopentenylpyrophosphate (IPP) 
is one prototype of these phosphorylated nonpeptidic ligands. Overproduction of these 
metabolites may allow γδ T cells to target cells with deranged metabolic activity of the 
mevalonate pathway (185). Notably, an increased expression of hydroxy-
methylglutaryl-CoA reductase (HMGR), the rate limiting enzyme of the mevalonate 
pathway, has been reported in hematological malignancies and mammary carcinoma 
cells (186). Accumulated IPP in tumour cells is suggested to bind the Vγ9/Vδ2 TCR, 
thus acting as an activation signal, although the mode of recognition of this ligand 
remains unclear. When activated they release pro-inflammatory chemokines  (e.g. MIP-
1, RANTES) and T-helper cell type 1 (Th1) cytokines (e.g. IFNγ and TNFα), and 
proliferate in the presence of IL-2. Some hemopoietic tumor cell lines, such as the 
Daudi Burkitt's lymphoma and the RPMI 8226 myeloma line are spontaneously 
recognized and lysed by Vγ9/Vδ2 T cells in vitro (187,188). The molecular basis of 
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such a spontaneous tumor cell recognition has not been fully elucidated yet. One 
possibility is that tumor cells express induced self ligands like stress-inducible MHC 
class I-related MICA/MICB molecules, heat shock proteins (HSP), and/or other ligands 
that are recognized through the Vγ9/Vδ2 TCR or through coreceptors like the NK 
receptor member D of the lectin-like receptor family (NKG2D)(189). Most tumour cells 
express ligands for the NKG2D receptor such as the MHC class I chain-related genes 
(MIC) A/B, and proteins of the UL16-binding protein (ULBP) family (190). These 
molecules bind to the NKG2D receptor expressed on Vγ9/Vδ2 T cells, acting also as an 
activation signal (Fig. 11).  
 
Fig. 11: Tumour cell killing capacity of activated Vγ9/Vδ2 T cells. Vγ9/Vδ2 T cells recognize via 
their TCR isoprenoid metabolites such as IPP that may accumulate in tumour cells. They also 
recognize via NKG2D stress-induced ligands that are often expressed on tumour cells. Stimulation 
of either or both receptors activates Vγ9/Vδ2 T cells and leads to tumour cell lysis. 
 
After recognition of these molecules, γδ T-cells become activated to produce cytokines 
and eliminate a target cell. Killing is performed via the perforin / granzyme pathway 
and death-receptor-dependent pathways (180). Upon activation of a cytotoxic 
lymphocyte, granules containing perforin and granzymes are released in the synaptic 
cleft between the killer and target cell. Perforin makes pores in endosomes and 
granzymes enter in the cytoplasm of the target cells and activate apoptosis-pathway 
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(180). There are different death-receptor-dependent pathways involved in the killing of 
tumor cells (181). The most important death ligands are FasL, TRAIL and TNF. These 
death domain-containing adaptor molecules start the proteolytic caspase cascade by 
activating caspase-8 and -3 in the tumor cell, leading to apoptosis. Recently, it has been 
shown that activated Vγ9/Vδ2 T cells are a novel type of professional APC (191) 
similarly to DCs, macrophages and B cells. APCs present MHC molecules linked to a 
endogenous or exogenous peptide on the cell surface and interact with the αβ TCR of 
CD8+ T cells and CD4+ T cells. Activated Vγ9/Vδ2 T cells have been shown to present 
all these functions, these cells efficiently processed and displayed antigens and provide 
costimulatory signals sufficient for strong induction of naïve αβ T cell proliferation and 
differentiation (192). Thus, Vγ9/Vδ2 T cells have the ability to bridge innate and 
adaptive immune responses. 
Vγ9/Vδ2 T cells are important contributors to innate and adaptive immune responses 
against tumor cells and pathogens, then it is possible to develop a novel strategy for 
treatment of solid and haematological cancer utilizing the mode of action of γδ T cells. 
 
Bisphosphonates and γδ T cells 
 
Bisphosphonates (BPs) are synthetic drugs that prevent bone resorption and are used for 
the treatment of Paget’s disease, tumour-associated bone diseases and osteoporosis. 
Based on their chemical structure, BPs are traditionally divided into two 
pharmacological classes with distinct molecular mechanisms of action: nitrogen- 
containing (N-) and non-nitrogen containing (non-N) drugs. Bisphosphonates that lack a 
nitrogen atom are metabolized into non-hydrolyzable proapoptotic ATP analogues that 
accumulate in the cytosol of osteoclasts (193). The resulting accumulation of non-
hydrolysable analogues of ATP induces osteoclast apoptosis and inhibits bone resorption 
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(194). By contrast, N-BPs interfere with a specific enzyme in the mevalonate pathway, 
farnesyl pyrophosphate synthase (FPPS), thereby depleting the osteoclasts of isoprenoid 
lipids (195,196). More specifically, FPPS inhibition by N-BPs blocks the covalent 
attachment of isoprenyl chains to small GTPases (e.g., Ras, Rac, Rho), which is crucial 
for their intracellular localization and functions in osteoclasts. In addition to the effects 
on the function of small GTPases, the disruption of the mevalonate pathway by N-BPs 
results in the accumulation of isopentenyl pyrophosphate (IPP), which is then converted  
to a cytotoxic adenosine triphosphate analogue (ApppI) that can directly induce 
osteoclast apoptosis (197,198). Thus, N-BPs may exert their pharmacological effects on 
osteoclasts through the formation of ApppI or via the inhibition of protein prenylation, 
particularly of small GTPases. Moreover, N-BPs have been tested for a wide range of 
solid and haematopoietic cancers. In vitro studies show that N-BPs have cytostatic 
activity against tumor cells, induce apoptosis and also inhibit cell adhesion. Zoledronic 
acid (ZA) is a newer N-BP with a tertiary amino group included within a ring structure. 
It can be considered the most potent and widely used intravenous BP that prevent the 
delayed onset of skeletal related event (SRE) in patients with bone metastases from any 
type of tumour and also for the treatment of hypercalcemia of malignancy (199,200). 
ZA is approved for the treatment of patients with bone metastasis from breast cancer, 
hormone refractory prostate cancer, as well as other solid tumors and multiple myeloma 
(201). A very interesting property of N-BPs in antitumor immune responses is the 
ability to activate Vγ9Vδ2 T cells. Through inhibition of FPPS of  the mevalonate 
pathway,  N-BPs trigger the intracellular accumulation of IPP and  exerting strong 
activation of Vγ9Vδ2 T cells. Furthermore, zoledronate induces functional changes in 
Vγ9Vδ2 T cell subsets (202). In vivo, it promotes the differentiation of Vγ9Vδ2 T cells 
toward CD45RA-CD27- γδ T cells, which produce interferon-γ and exert cytotoxicity, 
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while decreasing CD45RA+ CD27+ naive and CD45RA-CD27+ memory γδ T cells 
(202). This effect is specific to Vγ9Vδ2 T cells. Neither human γδ T cells expressing the 
Vγ9Vδ1 TCR, nor human αβ T cells, monocytes, NK or B cells are responsive to N-BPs 
(202,203).  
Previous studies have demonstrated that zoledronate sensitizes chemotherapy-resistant 
tumor target cells (prostate,breast and lung cancer) to Vγ9Vδ2 T cell cytotoxicity, 
rendering these cancer cell lines highly susceptible to Vγ9Vδ2 T cell-mediated killing 
(204). Recently, interest has emerged on the use of zoledronate in CML, because this 
drug synergistically augments the anti-Ph+ leukaemia activity of imatinib both in vitro 
and in vivo (205,206), and inhibits proliferation and induces apoptosis of imatinib-
resistant CML cells  (207). D’Asaro et al. showed that pre-treatment of sensitive and 
resistant CML cells with zoledronate alone or in combination with imatinib significantly 
increased killing by Vγ9Vδ2 T lymphocytes (208). They showed also that Vγ9Vδ2 T 
cells kill cells freshly isolated from patients with CML, at time of diagnosis and before 
therapy, but exclusively when cells were pretreated with zoledronate alone or in 
combination with imatinib (208). 
The unique ability of bisposphonates to render tumour cells susceptible to Vγ9Vδ2 T 
cell attack makes these drugs particularly interesting candidates for use in γδ T cell 
therapy. 
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AIMS 
 
The overall aims of this project were to assess the release of exosomes by LAMA84 
CML cell lines and to elucidate their role in angiogenesis. To evaluate this, I tested if the 
addition of those exosomes to human vascular endothelial cells (HUVEC) affects 
several step of in vitro angiogenesis including motility, cytokine production, cell 
adhesion and cell signalling, as well as stimulation of angiogenesis in a nude mouse 
assay. To confirm the data obtained with exosomes derived from LAMA84 cells, I used 
exosomes isolated from blood of CML patients to understand better how CML cells can 
induce an angiogenic phenotype. Another field of investigation was the study of the 
effects of exosomes on γδ T cells. These lymphocytes exhibit a potent MHC-
unrestricted lytic activity against several tumor cells and are able to kill CML cells 
pretreated with zoledronic acid. Zoledronic acid is a syntethic aminobiphosphonate that 
is able to activate γδ T cells, augments the anti-Ph+ leukemia activity of imatinib both in 
vitro and in vivo and inhibits proliferation and induces apoptosis of imatinib-resistant 
CML cells. I started to analyze if exosomes from CML cell lines have an activatory or 
inhibitory effects on these lymphocytes and if zoledronic acid affect the release or the 
effects of exosomes. The understanding of the mechanism of communication between 
leukemic cells and the microenvironment and the mechanism by which tumor cells can 
escape immune system could promote the development of new therapies to overcome 
drug resistance observed sometimes in the treatment of CML.  
The more specific aims were to investigate:  
• Detect and characterize microvesicles released from CML cell lines (western 
blot and enzymatic assays) 
• Evaluate the effects of  exosomes on endothelial cells  (motility, wound healing, 
adhesion assays) 
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• Evaluate the effects of exosomes on  in vivo angiogenesis assay 
• Evaluate the effects of exosomes on γδ T cells functions (cytokines release, 
NKG2D, CD69 and CD25 expression) 
• Evaluate the effect of zoledronic acid on the release and effects of exosomes  
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Materials and Methods 
 
Cell culture 
 
LAMA84 and K562 chronic myelogenous cells, were cultured in RPMI 1640 
(Euroclone UK) supplemented with 10% FBS (Euroclone UK), 2mM L-glutamine 
(Euroclone UK), 100 U/ml penicillin and 100 µg/ml streptomycin. Human umbilical 
vein endothelial cells (HUVEC, Lonza, Clonetics, Verviers, Belgium) were grown in 
endothelial growth medium (EGM) supplemented with Hydrocortisone, hFGF-B, 2 ml; 
VEGF, 0.5 ml; R3-IGF-1, 0.5 ml; Ascorbic Acid, 0.5 ml; Heparin, 0.5 ml; FBS, 10 ml; 
hEGF, 0.5 ml; GA-1000, 0.5 ml. LAMA84 and K562 cells were maintained at 
concentration of 0,3x106/ml to grown, and were expanded at 1x106/ml to recover 
exosomes. For treatment with Zoledronic acid (gift from Novartis Pharma, Milan Italy), 
5 µM/ml of the drug was added when K562 cells were seeded for exosomes at 
concentration of at 1x106/ml.  HUVEC cells were cultured in Petri dish, were harvested 
using trypsin-PBS 1:1 and seeded for the experiment. Cultures are placed in a 
humidified 95% air and 5% CO2 atmosphere at 37° C. 
 
PBMC isolation 
 
Human blood samples were obtained from healthy donors, after written informed 
consent was obtained, in accordance with the Declaration of Helsinki guidelines and 
University of Palermo Ethics committee. Human peripheral blood mononuclear cells 
(PBMC) were isolated using the Ficoll-Paque (GE Helthcare-Bio Science, Uppsala, 
Sweden) separation technique. Whole blood was diluted in RPMI, layered over Ficoll-
Paque and centrifuged at 1400 × g for 20 min. The mononuclear cells (interphase layer) 
were collected, washed twice in complete medium (RPMI 1640 medium, 10% FBS, 1% 
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penicillin-streptomycin) and finally resuspended in complete medium. PBMC were 
cultured at concentration of 1x106/ml to recover exosomes. 
 
γδ T cell isolation 
 
For γδ T cells isolation, whole blood were taken from healthy donors at Cardiff 
University, according to the local ethical guidelines on experimentation with human 
samples. Blood was layered on Lymphoprep (Axis-Shield), and centrifuged at 1700 rpm 
for 20 min. PBMC were recovered and washed twice with MACS buffer (5mM EDTA; 
2%FBS; PBS 1X) and centrifuged at 1500 rpm for 10 min and 1000 rpm for 10 min. 
Pellet was resuspended in 1ml of MACS buffer and was added a blocking IgG antibody 
(1:100) for 10 min on ice. The cells were staining with Vγ9 PE-Cy5 (1:400) for 15 min 
on ice. Cells were washed in MACS buffer at 1300 rpm for 8 min and resuspended in 
400 µl MACS buffer plus anti-PE microbeads (Milteny) for 15 min in the fridge. Cells 
were resuspended in 2 ml of MACS buffer and placed onto LS column. After 3 washes 
with MACS buffer,  γδ T cells were recovered a 15ml falcon tube. γδ T cells was 
counted and seeded for all experiment at 50000 cells/well at 37 °C in 5% CO2. Cultures 
were incubated in 96 well plate overnight in the presence of 10 nM HMB-PP to activate 
Vγ9/Vδ2 T cells, and 20 U/mL interleukin-2 (IL-2) (Proleukin, Chiron).  
 
Exosome isolation 
 
Exosomes produced by LAMA84, K562 treated with ZA and K562 cells during a 24 hr 
culture period, were isolated from conditioned culture medium supplemented with 10% 
FBS (previously ultracentrifuged) by differential centrifugation. Conditioned medium 
(CM) was recovered after 24h. CM were centrifuged at 300 g x 5’, 3000 g x 10’, 10000 
g x 20’. CM was filtered (0,22µm filter) and was ultracentrifuged in “Ultra Clear-Queck 
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Seal” tubes at 100000 g x1h30’. Pellet was washed and then resuspended in PBS.  
 
30%sucrose/D2O cushion 
 
To further verify the identity of vesicles as exosomes, vesicles were isolated on a 30% 
sucrose/D2O cushion (density of 1.13–1.19 g/mL), as described by Lamparski et al (66) 
Exosomes from differential centrifugation method were resuspended in 25 ml of PBS. 
4ml of 30%sucrose/D2O was loaded on the bottom of the ultracentrifuge tube and 
diluited exosomes were layered above the sucrose cushion, gently without disturbing 
the interface. Samples were ultracentrifuged at 100000xg, 4°C for 75 min in SW 28 
rotor. The cushion, which now contains exosomes,  was recovered with a 5ml syringe 
from the side of the tube. The cushion was transferred to a fresh ultracentrifuge tube and 
were added 40 ml of PBS. Samples were ultracentrifuge at 100000xg 70 min in 70 Ti 
rotor. Pellet was resuspended in PBS. Exosome protein content was determined by the 
Bradford method. On average,  the amount of exosomes obtained  was 100 µg/40 ml 
from LAMA84 and K562 conditioned medium and 50 µg/40 ml from K562 treated with 
ZA. 
 
Scanning Electron Microscopy 
 
Exosomes were next examined by scanning electron microscopy analysis. They were 
fixed with 2% glutaraldehyde in PBS for 10 min, attached onto stubs, coated with gold 
in a sputterer (Sputter Coater 150A, Edwards, UK) and observed using a field emission 
scanning electron microscope (FEGESEM QUANTA 200 FEI) at working voltage 30 
kV. 
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Patients 
 
Blood samples were obtained from two newly diagnosed CML patients. Informed 
consent was obtained from patients, according to the Declaration of Helsinki and with 
hospital Ethics Committee approval. Whole blood samples were treated with red blood 
cell lysing buffer (Sigma, St. Louis, MO) for 2 min at room temperature, then 
centrifuged at 350g for 7 min to recover and discard lysed red cells. The interphase 
layer containing CML cells was collected, resuspended in PBS and lysated for controls. 
Exosomes released in fresh patient’s plasma were prepared with the same protocol of 
CML cell lines. 
 
Western blot and immunoprecipitation assay 
 
CML cells and exosomes were lysed in lysis buffer (300 mM NaCl, 50 mM Tris HCl pH 
7.6, 0.1% Triton, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 4 mM EDTA, 
2 mM sodium orthovanadate, 10mMNaPPI, 100mMNaF) on ice for 1h. The cell lysates 
were clarified at high speed centrifugation for 15 min and an aliquot of the supernatant 
was assayed to determine protein concentration by the Bradford method.  
Total cell or exosome lysates were subjected to SDS-PAGE electrophoresis and 
immunoblot. Antibodies used in the experiments were: HSC70, CD63 and VCAM-1 
(Santa Cruz Biotechnology, Santa Cruz, CA), actin, MAPK and phosphoMAPK (Cell 
Signaling Technology, Beverly, MA). Five million HUVEC were incubated with 50 
µg/ml of LAMA 84 exosomes for 6 hr or with 10 ng/ml TNF a for 2 hr (positive 
control) or with low serum medium for 6 hr (negative control) and processed for 
immunoprecipitation experiments using precleared lysates. Samples were resolved in 
8% SDSPAGE followed by immunoblotting with anti-VCAM1. Aliquots of the 
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precleared cell lysates were resolved independently by 8% SDS-PAGE and examined 
for actin quantity as a surrogate of IP input (named as starting material or St) . 
 
Acetylcholinesterase assay 
 
A total of 10 µg of exosomes in 100 µl of PBS and 10 µg of total cell lysate  were 
resuspended in a solution of 1.25 mM acetylthiocoline and 0.1 mM 5,5’-dithiobis (2-
nitrobenzoic acid) in a final volume of 1 ml. The incubation was carried out in cuvettes 
at 37 °C, and the change in absorbance at 412 nm was followed  at different time points 
(from 0 to 180 min). 
 
Flow cytometry for VCAM1 
 
Expression of HUVEC cell surface VCAM-1 was determined by flow cytometry 
analysis. HUVEC were treated with or without 50 µg/ml of LAMA 84-exosomes in low 
serum medium (EGM:RPMI, 1:9). 500,000 cells were washed in PBS and incubated 
with 0.5 lg VCAM-1-FITC (Santa Cruz Biotechnology, Santa Cruz, CA) for 15 min at 
4°C. Viable cells were gated by forward and side scatter and the analysis was performed 
on 100,000 acquired events for each sample. Samples were analyzed on a FACS Calibur 
with the use of the CellQuest software (BD Biosciences). 
 
Flow cytometry of VCAM-1 expression on the surface of latex bead-coupled 
exosomes 
 
Exosomes are too small for FACScan analysis, and therefore were bound  to surfactant-
free white aldehyde/sulfate latex beads, 4 µm diameter (Interfacial; Dynamics, Portland, 
OR). Beads were incubated with 30 µg of exosomes for 15 min and then for 2h at room 
temperature in a final volume of 1 ml PBS. Glycine (100 mM) in PBS was added to the 
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beads at room temperature to saturate the remaining binding sites. Beads were then 
washed in PBS/0,5% BSA and resuspended in 0,5 ml of  PBS/0,5% BSA . 10 µl of 
coated beads were incubated with 50 µl VCAM-1 antibody diluted in PBS/0,5% BSA 
for 30 min, washed twice with PBS/0,5% BSA and analyzed with a FACScan and 
CellQuest software (241).  
 
Flow cytometry for NKG2D, CD69, CD25, IFNγ and TNFα 
 
γδ T cells after overnight incubation with 1,5,10 µg/ml of exosomes from K562 and 
K562 zol were stimulated with 10 µg/ml Brefeldin A (Sigma)  for 4 hours. The plate 
was centrifuged at 1300 rpm for 2 min and washed with PBS. Cell pellet was stained 
with Live/Dead aqua (1:10) (Invitrogen) at room temperature for 15 min. Cells were 
washed with PBS, spinned down at 1300 rpm for 2 min and resuspend with IgG 
blocking antibody (1:100) in 50 µl of  FACS buffer (PBS containing 2% bovine serum 
albumin and 0.02% sodium azide). Cells were incubated for 15 min in dark on ice and 
washed on FACS. Cells were staining with surface antigens: CD69 FITC (Pharmigen); 
CD25 PE-Cy7(BD biosciences); CD3 APCH7 (BD biosciences); Vγ9 PE-Cy5 (Coulter); 
NKG2D PE (Pharmigen). At the same time was prepared also a control Isotype for 
surface antigens with: IgG1 FITC; Vγ9 PE-Cy5; CD3 APCH7; IgG1 PE-Cy7; IgG1 PE. 
Cells were staining for 20 min on ice and washed twice in PBS. Were added 50 µl of 
Fixation buffer to fix surface staining, for 15 min room temperature in dark. To 
eliminate all fixation buffer, cells were washed twice in PBS and washed with 50 µl of  
Permeabilization buffer. At this point cells were stained for intracellular cytokines with 
IFNγ Pacific Blue (eBiosciences) and TNFα APC (BD Biosciences), and were stained 
also with control Isotype: IgG1 Pacific blue and IgG1 APC. Cells were incubated 15 
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min room temperature in dark and washed with FACS buffer. Stained cells were 
analysed by eight-colour flow cytometry on a FACS CANTO II  (Becton Dickinson) 
using FlowJo software (Tree Star). 
 
Immunofluorescence and cell cytoskeleton analysis 
 
HUVEC monolayers were grown to confluence on coverslips coated with type I 
collagen (Calbiochem, Darmstadt, Germany) and were treated with increasing doses of 
CML exosomes or low serum medium for 6 hr to study VE cadherin, β-catenin protein 
distribution and expression level. After incubation with exosomes or BSA control, cells 
were fixed in 3.7% paraformaldehyde for 10 min followed by permeabilization with 
0.1% Triton X-100 for 3 min. Antibodies used in the experiments were: VE cadherin 
and b-catenin (1:100; Santa Cruz Biotechnology, Santa Cruz CA). Incubation with 
antibodies was performed in PBS with 1% BSA overnight at 4° C. Cells were stained 
with Texas Red-conjugated secondary antimouse antibodies (1:100; Molecular Probe, 
Eugene, OR) and analyzed by confocal microscopy (Olympus 1x70 with Melles Griot 
laser system). Analyses of the actin cytoskeleton were performed as described (ref20) 
The semi-quantitative analysis of fluorescence intensity was performed using IMAGE-J 
software (http://rsbweb.nih.gov/ij/).(242) 
 
RNA extraction and Real-Time PCR 
 
HUVEC cells were grown to confluence in 6-well plates and incubated for different 
times with the indicated stimuli. IL-8, VCAM-1, ICAM-1 transcript levels were 
measured by reverse transcription (RT) and TaqMan real-time quantitative polymerase 
chain reaction (RT-PCR) and analyzed as described (243) The following primers were 
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used: IL-8, HS00174103_m1; VCAM-1, HS 00174239 m1; ICAM-1, HS 00277001_m1 
and, GAPDH, Hs99999905 m1 (Applied Biosystems, Foster City, CA). GAPDH was 
used as the internal control. 
 
Motility assays 
 
Migration assays were performed following two standard protocols, Transwell 
chemotaxis chambers (NeuroProbe, Cabin John, MD) and wound repair assay. 
LAMA84 cells (2 x 106/ml) were suspended in serum-free RPMI 1640 medium 
supplemented with 0.1% BSA in transwell chemotaxis above 8 µm pore filters and 
exposed to chemoattractants with increased amount of exosomes (10-20-50 µg/ml), 10 
ng/ml of recombinant IL8 (Sigma, St. Louis, MO), or neutralizing antibodies anti IL8 (5 
µg/ml) (R&D system, Minneapolis, MN) as indicated. Filters were removed after 6 hr, 
fixed in ethanol and stained with Diff-Quick (Medion Diagnostics GmbH, Du¨dingen, 
Switzerland). Each test group was tested in three independent experiments; the number 
of migrating cells in five high-power fields per well were counted at 400x 
magnification. For the wound healing assay, a wound was created by manually scraping 
the confluent endothelial cell monolayer with a p1000 pipette tip. After washing with 
PBS, cells were incubated for 3 hr with medium containing exosomes or control 
medium without exosomes. Images of cell-free spaces were taken with a digital camera 
at the indicated times and measured manually with the IMAGE-J software 
(http://rsbweb.nih.gov/ij/) (242). The data are reported as the percentage of the distance 
migrated relative to the control cultures for each experiment. 
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Adhesion assay 
 
For Adhesion assays HUVEC monolayer was incubated for 6 hr with 10, 20, 50 µg/ml 
of LAMA84 exosomes, 50 µg/ml of LAMA84 exosomes plus anti-actin antibody (5 
µg/ml), 10 ng/ml of recombinant IL8, 50 µg/ml of CML patients exosomes, EGM as 
positive control, 50 µg/ml of exosomes plus neutralizing antibody anti-IL8 (5 µg/ml), 
50 µg/ml of PBMC exosomes and low serum medium as negative control. After 
treatment, cells were washed with PBS and 0.5x106 CML cells were added for 1 hr at 
37°C. Adherent cells were stained with hematoxylin/eosin, each test group was assayed 
in triplicate; five high power (400X) fields were counted for each condition. 
 
ELISA 
 
HUVEC conditioned medium (CM) was collected from cells stimulated for 6 hr with 20 
and 50 µg/ml of PBMC exosomes, 10,20,50 µg/ml of LAMA84 exosomes. CM aliquots 
were centrifuged to remove cellular debris and IL-8 protein concentrations were 
quantified using an ELISA kit (R&D Systems, Minneapolis), according to the 
manufacturer’s protocol. IL8 was also measured directly in LAMA84 exosomes 
(10,20,50 µg/ml) 
 
HUVEC tube formation on Matrigel 
 
Matrigel was used to test the effects of exosomes on in vitro vascular tube formation as 
described (ref22). HUVEC were plated on Matrigel at concentration of 70000 cells/well 
in endothelial basal medium containing 0.2% of  FBS, and 50 µg/ml of LAMA84 
exosomes, 50 µg/ml of LAMA84 exosomes plus anti-actin antibody (5 µg/ml), 10 ng/ml 
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of recombinant IL8, 50 µg/ml of CML patients exosomes, EGM as positive control, 50 
µg/ml of exosomes plus neutralizing antibody anti-IL8 (5 µg/ml), 50 µg/ml of PBMC 
exosomes and low serum medium as negative control were added to wells.  Cells were 
incubated for 6 hr and then evaluated by phase-contrast microscopy and photographed.  
 
Matrigel plug assay 
 
All animal experiments were conducted in full compliance with University of Palermo 
and Italian Legislation for Animal Care. Four week old BALB/c nude mice (Charles 
River Laboratorie International, Wilmington, MA) were injected subcutaneously with 
400 µl Matrigel (BD Biosciences Pharmingen, San Diego, CA) containing 100 µg 
LAMA84-derived exosomes with or without 10 lg/ml non specific anti-actin antibody 
or anti-IL-8 neutralizing antibody or PBS (negative control). The degree of 
vascularization was evaluated by determination of hemoglobin content using the 
Drabkin method (Drabkin’s reagent kit, Sigma Saint Louis, Missouri) (244) 
 
Statistics 
 
Data were expressed as means ± SEMs of the indicated number of experiments. 
Statistical analysis was performed by using a unpaired Student’s t test. Differences were 
considered to be significant when p values were <0.05. 
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Results and Discussion 
 
Characterization of the vesicles released from  LAMA84, K562 and K562 treated 
with zoledronic acid CML cell lines 
 
I examined the ability of LAMA84, K562 and K562 treated with 5 µM zoledronic acid 
(ZA) cells to release exosomes into the culture medium during a 24 hr period. Before 
the recover of the medium I performed an acridina-orange/BrEt to check the vitality of 
the cells. The percentage of apoptotic cells were less than 3% (Fig. 12), this result allow 
to exclude the presence of apoptotic bodies in the pellet after the ultra centrifugation. 
 
Fig. 12:  Cultured LAMA84 (a) and K562 (b) CML cells (106/ml) for 24h revealed a small 
percentage of apoptotic cells (<3%) 
 
Vesicles secreted by LAMA84 CML cells were also purified on a sucrose gradient and 
analysed by scanning electron microscope (Fig. 13a) and Western blotting using 
antibodies specific for HSC 70 and CD63. These proteins were detected in cell lysates 
and found more expressed in exosome fractions (Fig. 13b). Acetylcholinesterase 
activity, a characteristic enzyme localized in exosomes, was found associated with the 
exosome fraction while negligible amounts were found in conditioned medium deprived 
of exosomes (Fig. 13c). 
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Fig. 13: (a) Exosomes released by LAMA84 cells observed by scanning electron microscopy. (b) 
Detection of Hsc 70 and CD63 in 30 µg of exosomes purified after ultracentrifugation on 30% 
sucrose/D2O gradient (lane 1) and 30 µg of cell lysate (lane 2). (c) Acetylcholinesterase assay. The 
activity of acetylcholinesterase, an exosome-specific protein marker, was determined in exosomes 
(10 µg) (▪), total cell lysates (10 µg) (♦), exosome-deprived Fbs (▲) and exosome-deprived 
conditioned medium (CM) (■) as negative control 
 
 
Exosomes purified from whole blood of 2 patients with chronic myelogenous leukemia 
displayed same properties of vesicles isolated from LAMA84 cells (fig.14). 
 
Fig. 14: Characterization of exosomes from CML patients. Exosomes are enriched in HSC70 and 
CD63 
 
 
I also characterized exosomes from K562 and K562 treated with zoledronic acid for 
HSC70, CD63 and Acetylcholinesterase enzyme (fig.15). 
b 
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Fig. 15: (a)  Detection of Hsc 70 and CD63 in 30 ug of exosomes from K562 and K562zol purified 
after ultracentrifugation on 30% sucrose/D2O gradient (lane 2 and lane 4) and 30 µg of cell lysate 
(lane 1 and lane 3). (b,c) Acetylcholinesterase assay. The activity of acetylcholinesterase, an 
exosome-specific protein marker, was determined in exosomes (10 µg) (pink lane), total cell lysates 
(10 µg) (green lane), exosome-deprived Fbs (blue lane)  as negative control. 
 
 
It is important to underline that the treatment with 5 µM of ZA affect the release of 
exosomes from K562 cells. On average, I obtained 100 µg of exosomes/40 ml of K562 
conditioned medium, while after the treatment with ZA the amount recovered is 50 µg 
of exosomes/40 ml.  
Scanning electron microscope, Hsc70, CD63 and acetylcholinesterase confirmed that 
the vesicles released from LAMA 84, K562, K562 treated with zoledronic acid CML 
cell lines were exosomes. 
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Exosomes treatment of HUVECs induces cell-cell adhesion molecules 
 
To evaluate if exosomes shed by LAMA84 are able to affect cell-cell adhesion 
molecules mRNA expression, I treated HUVECs with different amount of exosomes for 
different times (6h, 12h, 24h).  
 
 
Fig. 16:  ICAM1 (a) and VCAM1 (b) mRNA expression increased in a time- and dose-dependent 
(10, 20, 50 lg/ml) manner after addition of exosomes to endothelial cell monolayer. Exosome-
deprived conditioned medium (CM-Ex) and low-serum medium were used as negative controls.  
 
 
As shown in figure 16 a and b, addition of increasing doses of exosomes to endothelial 
monolayer caused a dose- and time-dependent increase in  VCAM-1 (13 fold increase) 
and ICAM-1 (6 fold increase) mRNA expression (p≤ 0.01). 
Figure 17a shows that incubation of HUVEC with LAMA84 exosomes or TNFα, used 
as positive control, induced an increase of VCAM1 protein levels. FACS analysis 
confirmed that incubation of HUVEC with LAMA84 exosomes resulted in the detection 
of VCAM-1 on the surface of HUVEC (Fig. 17b). 
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Fig. 17: a) Immunoprecipitation assay with anti-VCAM1 antibody. HUVEC were incubated for 6 
hr with low-serum medium (lane 1); 50 lg/ml LAMA84 exosomes (lane 2) or 10 ng/ml TNFα (lane 
3); results indicate an increased amount of VCAM-1 in exosome-treated cells. b) Representative  
overlay histogram showing an increase of surface expression of VCAM 1 on HUVEC treated with 
50 lg/ml of LAMA84 exosomes (solid line) compared untreated HUVEC, as control (dot line) 
 
 
Immunoprecipitation and western blotting assays showed that VCAM-1 was 
undetectable in LAMA84 exosomes  and flow cytometry analysis of latex bead-coupled 
exosomes confirmed the absence of VCAM-1 on membrane particles (fig 18). 
 
 
Fig. 18: Representative overlay histogram showing 10 µl of latex beads coupled with 30 µg of 
LAMA84 exosomes (black line) or BSA (grey line) tested for surface expression of VCAM-1. No 
shift in fluorescence was observed when exosomes were stained with VCAM-1 antibody. 
 
 
Cell–cell interaction mediated through cell-adhesion molecules occurs after endothelial 
activation in angiogenesis. In leukaemia, the adhesion molecules have been thought to 
play an important role in various processes, including release of blast cells from bone 
marrow to the circulation, homing of blast cells to various organs and interaction of 
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blast cells with each other (209). These data showed that the amount of ICAM1 and 
VCAM1 was significantly higher in cells treated with increasing doses of LAMA84 
exosomes. To support this statement VCAM1 was detected in exosomes-treated and 
untreated HUVEC cells. FACS analysis shows an increase in surface expression of 
VCAM1 in HUVEC cells after treatment with exosomes compared to untreated 
HUVEC cells.  VCAM1 was tested also on exosomes directly, and the absence of 
surface expression confirm that this protein was produced by HUVEC and not 
transferred by adding LAMA84 exosomes. Then exosomes can be have a role on the 
interaction between CML cells and endothelium. Infact, it is described that leukemic 
cells interact with endothelium through adhesion molecules and cell adhesion is 
necessary to trigger the survival signals on leukemic cells. The increased expression of 
cell-cell adhesion molecules on endothelial cells may be associated with an augmented 
dissemination of  leukemia blast cells to extramedullary sites (210), because ICAM1 
and VCAM1 mediated the adhesion of myeloblasts to activated endothelium (211).  
I also tested also the expression of IL8, IL6, VEGF and TGFβ genes that are involved in 
tumor growth and angiogenesis. HUVECs treated with exosomes from LAMA84 
induced a dose dependent increase in IL8 mRNA (fig.19).  
 
 
Fig. 19: IL8 mRNA expression increased in a dose-dependent (10, 20, 50 lg/ml) manner after 
addition of exosomes to endothelial cell monolayer. Exosome-deprived conditioned medium (CM-
Ex) and low-serum medium were used as negative controls. 
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Increased IL8 mRNA production was statistically significant and reached approximately 
a 20-fold induction after 6 hr of stimulation of the endothelial monolayer with 50 µg/ml 
of vesicles. No effect was observed on IL-6, VEGF or TGF-β (data not shown). The use 
of IL-8 neutralizing antibody  inhibited exosome-stimulated increase of ICAM-1, 
VCAM-1 adhesion molecules and IL8 as shown in figure 20.  
 
 
Fig. 20: VCAM1, ICAM1 and IL8 mRNA expression in HUVEC treated for 12 h with low 
serummedium (Ctrl), Ctrl plus 10 lg/ml of a neutralizing anti-IL8 antibody, 50 lg/ml exosomes or 50 
lg/ml exosomes plus 10 lg/ml of a neutralizing anti-IL8 antibody. 
 
I evaluated also the release of IL8 into HUVEC conditioned medium and the data 
confirmed that there is an increase in the synthesis of IL8 in endothelial cells after 
treatment with exosomes. A small amount of IL8 was found in LAMA84 exosomes. No 
significant induction of IL-8 release was observed when HUVEC were stimulated with 
exosomes purified from PBMC (fig. 21). 
 
Fig. 31: Elisa Assay. Treatment with exosomes induce an increase in the release of IL8 by HUVEC. 
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I demonstrated increased mRNA and protein expression of interleukin-8 in exosomes-
stimulated HUVEC cells. IL-8, a member of the CXC family of chemokines, is best 
known for its leukocyte chemotactic properties and associated role in inflammatory and 
infectious diseases (212). IL8 has other biological functions in addition to its well-
recognized role in regulating inflammatory responses (213), it has been shown that IL8 
is a potent proangiogenic factor (214). It was demonstrated that IL8 has the ability to 
exert a strong effect on tumor microenvironment. For example, secretion of IL-8 from 
cancer cells can enhance the proliferation and survival of cancer cells through autocrine 
signaling pathways. In addition, tumor-derived IL-8 will activate endothelial cells in the 
tumor vasculature to promote angiogenesis and induce a chemotactic infiltration of 
neutrophils into the tumor site (215). It was demonstrated that IL8 plasma protein levels 
and IL8 mRNA expression by leukemic blasts were associated with a worse outcome in 
ALL (216) and CLL (217) patients,  and it was described that IL8 plasma concentration 
are significantly increased in patients with CML (218). These data shows that IL8 were 
able to enhance the ability of endothelial cell to support adhesion of CML cells, and 
exert its pro-adhesion effect by stimulating VCAM-1 and ICAM-1 expression on 
HUVEC. Involvement of IL8 in exosome-mediated increase of ICAM1 and VCAM1 
was also demonstrated by using recombinant IL8 and IL-8 neutralizing antibodies.  
 
Exosomes stimulate binding of CML cells to HUVEC monolayer 
 
A hallmark feature of leukemia progression is the adhesion of cancer cells to endothelial 
cells for extramedullary infiltration. Then, I tested the ability of leukemia cells to adhere 
to an endothelial monolayer to investigate functional effects of the observed increase of 
ICAM-1 and VCAM-1 expression in exosome-treated HUVECs. Figure 22a shows a 
dose-dependent increase in leukemia cell adhesion to HUVEC after 6 h treatments. 
Figure 22b shows the increase in adhesion of LAMA84 cells (arrows) to HUVEC 
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monolayer after a 6 hr treatment with 50 µg/ml of exosomes. Figure 22c shows that 
addition of recombinant IL-8 to endothelial cells causes an increase of CML cells 
adhesion to HUVEC monolayer similar to that produced by LAMA84 or CML patient 
exosomes. The addition of exosomes from CML patients to endothelial monolayer is 
similar to that produced by LAMA84 exosomes, while the treatment with exosomes 
from PBMC or with exosomes plus IL8 neutralizing antibody didn’t increase the 
adhesion of leukemic cells to endothelial cells. 
 
 
Fig. 22: a) Adhesion of LAMA84 cells to endothelial cell monolayer treated for 6 hr with different 
amount of LAMA84 exosomes or with EGM, used as positive control; b) Adhesion of LAMA84 cells 
to endothelial cell monolayer treated for 6 hr with LAMA84 exosomes observed at contrast phase 
microscopy; c) Adhesion of LAMA84 cells to HUVEC treated with 50 µg/ml of LAMA84 exosomes, 
50 µg/ml of exosomes plus antibodies anti actin (5 µg/ml), 10 ng/ml of recombinant IL8, 50 µg/ml of 
CML patients exosomes, EGM (as positive control), 50 µg/ml of exosomes plus neutralizing 
antibodies anti IL8 (5 µg/ml), 50 µg/ml of PBMCexosomes in low serum medium and low serum 
medium (as negative control). Values are the mean 6 SD of 5 fields in three independent 
experiments CTRL: control. *p≤ 0.05; **p≤0.01. 
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These data confirmed that CML cells exhibited increased adhesion to HUVEC 
monolayer when LAMA84 exosomes were added. Interestingly, the same effects was 
observed with exosomes from CML patients. The effect of IL8 neutralizing antibody, 
that didn’t increase the adhesion of leukemia cells to HUVEC monolayer, suggest that 
this chemokine may provide a supportive effects for CML cells in this angiogenic step.  
 
CML exosomes promote migration of endothelial cells 
 
In the angiogenic process one important step is the increase of the motility of the 
endothelial cells. Confluent, scrape-wounded endothelial cell monolayers were 
incubated with various concentrations of CML vesicles, and the percentage of closure 
was observed after 3 hr. Figure 23a shows that endothelial cell migration was 
significantly increased in exosome-treated cultures but not in the control medium.  
 
 
Fig. 23: (a) Confluent, scrape-wounded endothelial cell monolayer incubated with low 
serummedium (negative control), 50 µg/ml of LAMA84 exosomes, and EGM medium (positive 
control), for 3 hr. b) Percentage of closure of the wounded area measured after addition of different 
amount of exosomes; c)Effects of exosomes on endothelial cell migration as measured by Boyden 
chamber assay. Addition of exosomes (10, 20, 50 µg/ml) for 6 hr to the bottom wells of the chamber 
induced a dose-dependent increase of HUVEC migration. Values are the mean 6 SD of 3 fields in 
three independent experiments *p ≤ 0.05; **p≤ 0.01. 
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As positive control, EGM-treated cells migrated into the denuded area, almost 
completely covering the exposed surface after 3 hr. Measurement of wounded area 
evidenced, compared to control, a 55% percentage of closure when endothelial cells 
were treated with the dose of 50 µg/ml of exosomes (Fig.23b). I further analyzed the 
effects of exosomes on cell migration by Boyden chamber assay. Figure 15c shows that 
addition of a range of concentrations of vesicles (10–50 µg) to the bottom wells of the 
chamber caused, after 6 hr, a dose-dependent increase of CML cell migration. A similar, 
statistically significant, effect in the stimulation of endothelial cell migration was 
obtained when recombinant IL-8 or CML patients exosomes were added as 
chemoattractant in the Boyden assay (Fig.23c); on the contrary the presence of anti IL-8 
neutralizing antibodies or PBMC exosomes in the bottom wells of boyden chamber 
didn’t increase the motility of leukemia cells (Fig.24).  
 
 
 
Fig. 24: 50 µg/ml of LAMA84 exosomes, 50 µg/ml of LAMA84 exosomes plus antibodies anti actin 
(5 µg/ml), 10 ng/ml of recombinant IL8, 50 µg/ml of CML patients exosomes, EGM (as positive 
control), 50 µg/ml of LAMA84 exosomes plus neutralizing antibodies anti IL8 (5µg/ml), 50 µg/ml of 
PBMC-exosomes in low serum medium and low serum medium (as negative control) were added as 
chemoattractants to the bottom wells. 
 
 
Exosomes released from leukemia cells in close proximity of endothelial cells may also 
contribute in the exacerbation of endothelium activation and increase migration of 
endothelial cells during angiogenesis. 
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This data demonstrate that the chemotactic effects on endothelial cells were potentiated 
by LAMA84 and CML patients exosomes in a dose-dependent manner both in Boyden 
chamber and in a wound healing assay.  It was described that chemokines have been 
implicated in the migration and tissue infiltration of leukaemic cells (219), and here it 
has been demonstrated that the addition of IL-8 neutralizing antibodies to CML 
exosomes in both assays inhibited the process of cells motility thus reinforcing the role 
of  IL-8 in exosomes-induced cells migration. 
 
Exosome treatment alters VE-cadherin and β-catenin localization 
 
To investigate if alteration of cell junctional components could be responsible for the 
increase in cell motility, I evaluated the effects of exosomes on expression of VE-
cadherin and β-catenin. VE-cadherin is an endothelial-specific adhesion molecules 
which under normal condition, is located at adherens junctions and is essential for the 
mainteinance and control of endothelial cell contacts (220,221), and the association with 
β-catenin is required for junction stabilization. The extracellular domain of VE-cadherin 
mediates initial cell adhesion,whereas the cytosolic tail is required for interaction with 
the cytoskeleton and junctional strength, mediated through β-catenin (222). The 
functional role of VE-cadherin changes during early phases of angiogenesis. Endothelial 
cells treated with exosomes from LAMA84 cell lines show a delocalization of this 
molecule. VE-cadherin staining decreased in intensity and became patchy at the 
membrane concomitant with the appearance of a granular cytoplasmic staining in 
HUVEC treated with 50 µg/ml of exosomes, compared to control cells that had 
continuous peripheral VE-cadherin staining (Fig. 25b). I evaluated also the effect of 
exosomes on β-catenin, a protein that interact with VE-cadherin and is involved in 
signal transduction. HUVEC treated with exosomes show a reduction of membrane 
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immunostaining compared to control cells after 6h. The treatment with exosomes 
caused a translocation from the plasma membrane to the cytoplasm and nucleus (fig.25 
c and d). Furthermore, staining of actin filaments with rhodamine-conjugated phalloidin 
confirmed the alteration of endothelial integrity when exosomes are added to HUVEC 
monolayer (fig.25a).  
 
 
Fig. 25: (a) modification of cytoskeletal structures as observed with actin localization in HUVEC 
monolayer treated with 50 µg/ml of exosomes compared to control cells b) Analysis at confocal 
microscopy of VE Cadherin localization in HUVEC cells treated with LAMA84 exosomes revealed 
a decrease of immunostaining compared to untreated cells (control). (c) Decrease of 
immunostaining for β catenin in cell membranes was revealed after 6 hr incubation of HUVEC 
with 50 µg/ml of LAMA84 exosomes compared to control cells  (d) figure shows the translocation of 
b catenin in the cytoplasm and nucleus compared to control   
 
 
Treatment of HUVECs with LAMA84 exosomes induced a cytoskeletal reorganization 
with a concomitant translocation of VE-cadherin and β-catenin from cell surface to 
cytoplasm and nuclei. Overall, these results indicate that addition of exosomes to 
endothelial cells reduced intercellular adhesion, as a biological consequence of loss of 
zonulae adherens components, VE-cadherin and β-catenin. These loosen endothelial 
cell-to-cell contacts, is indicative of weakened cell-cell adhesion mechanism and may 
be responsible for increased motility (223).  
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In vitro Angiogenesis Assay 
 
To evaluate the effects of exosomes on in vitro models of angiogenesis, I performed an 
angiogenesis assay on Matrigel; as shown in figure 26, a treatment for 6h with 
exosomes from LAMA84 induce in HUVECs an endothelial network formation in a  
 
 
Fig. 26: Phase contrast micrographs showing that exosomes induce an endothelial network 
formation on matrigel. No tube formation is observed when HUVEC are plated in low-serum 
medium or in the presence of 50 µg/ml of exosomes plus neutralizing antibody against IL8 or with 
exosomes from PBMC; the addition to HUVEC cells of 50µg/ml of LAMA84 exosomes or 50 µg/ml 
of exosomes plus a nonspecific antibody against actin or exosomes from CML patients  caused the 
formation of capillary-like structures 
 
 
dose-dependent manner. I obtained the same results with the addition of recombinant 
IL8 or with exosomes from CML patients, while the treatment with exosomes from 
PBMC had no effect. The anti-IL8 neutralizing antibody inhibited exosome-induced 
tube formation while treatment of cells with an anti-actin antibody had no effect. 
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In vivo Angiogenesis Assay 
 
The angiogenic potential of LAMA84 exosomes was then assayed in vivo by examining 
the recruitment of vasculature into subcutaneously implanted Matrigel plugs containing 
exosomes. Figure 27 shows that the plugs containing LAMA84 exosomes and 
LAMA84 exosomes plus a non specific antibody (anti-actin antibody), became more 
vascularized than implants with PBS control or with exosomes plus an anti-IL8 
neutralizing antibody. This suggests that IL-8 is critical for vascular recruitment and 
organization in this model. This is supported by the increased haemoglobin 
concentration in the exosomes-containing Matrigel (Table 1). 
 
Fig. 27:  Matrigel plug containing LAMA84 exosomes stimulate angiogenesis in nude mice. Ctrl: 
Negative control (Matrigel plus PBS), Ex + Ab nIL8: LAMA84 exosomes (100 µg) plus 10 µg/ml of 
an antibody neutralizing anti-IL8, Ex + Ab Actin: LAMA84 exosomes (100 µg) plus 10 µg/ml of a 
non specific antibody against actin, Ex LAMA84: LAMA84 exosomes (100 µg). 
 
 
 
 
An important aspect of tumor progression is tumor vascularization, and tube formation 
of endothelial cells is one of the key steps of angiogenesis. Increased vascularization is 
seen in AML (224), ALL (225) and also CML (226) patients show an increase in the 
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number of blood vessels but little is know about angiogenesis and angiogenesis-related 
molecules in leukemia, while there are many data about the effect of exosomes on solid 
tumor angiogenesis. Skog et al. have showed that glioblastoma tumor cells release 
different types of microvesicles including exosomes that contain mRNA, miRNA and 
proteins that may stimulate endothelial cells to acquire an angiogenic phenotype (126). 
It has been demonstrated that exosomes of human SW480 colon carcinoma cells are 
enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells, 
suggesting that microvesicles from cancer cells can be involved in tumor growth and 
metastasis by facilitating angiogenesis-related processes (227). The role of exosomes in 
metastasis has been also demonstrated in melanoma cells in a study by Hood and 
collaborators. They found that exosomes modulated both angiogenic and immunological 
cytokine signalling, thus serving as paracrine nanocarriers that might prepare distal sites 
for the arrest of metastatic cells (123). 
Here, both in vitro and in vivo assays demonstrated that LAMA84 and CML patients 
exosomes stimulates endothelial cell proliferation and capillary-tube organization, 
which can be blocked by neutralizing anti-IL-8 Abs, reinforcing the role of IL-8 in 
exosomes-induced vascularization and angiogenesis. These data support the role of 
exosomes in leukemic microenvironment as important mediators of tumor growth, 
progression and angiogenesis. 
 
Exosomes trigger phosphorylation of MAPK p42/44 
 
I analyzed MAPK signalling after interaction between endothelial cells and purified  
exosomes to begin to understand the molecular pathways through which exosomes 
affect angiogenesis. MAPK is a key signalling pathway activated in endothelial cells 
after binding of angiogenic factors (228). Crosstalk between MAPK and other 
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signalling pathways can further stimulate angiogenesis (229). As shown in figure 28 
stimulation of HUVEC with 50 µg/ml exosomes caused a time-dependent 
phosporylation of MAPK p42/44. The role of ERK activation in angiogenic growth 
factor signaling has been well established (230). ERK activation is probably required 
for the growth factor-induced secretion of angiogenic factors from tumor cells (231). 
The strong activation of ERK1/2 in endothelial cells early, after the exosomes addition 
suggest that these exosomes exert a specific stimulus for endothelial cell function. 
 
 
Fig. 28: : Western blot analysis of pMAPK and MAPK in HUVEC treated with 50 µg of LAMA84 
exosomes. HUVEC were starved for 3 hr with serum free medium and then treated with 50 µg of 
LAMA 84 exosomes for 15 min (lane 3) and 30 min (lane 4), or with low serum medium alone for 15 
min (lane 1) and 30 min (lane 2) as control. 
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Effects of exosomes on γδ T cell function 
 
The ability of tumor cells to evade or suppress an active immune response is considered 
to be a significant factor in the development and progression of tumors. It has been 
shown that  cancer patients, in particular those with malignant effusions such as ascites, 
produce enormous amounts of exosomes in vivo and, instead of boosted anti-cancer 
immunity, they succumb to the cancer with a deranged immune system (48). Increasing 
clinical and experimental evidence shows that cancer cells produce exosomes which 
affect cytotoxic ability of NK- and T cells and thus assist cancers in their immune 
evasion. Consequently, tumor-derived exosomes might be vehicles for 
immunosuppression with negative impact on the immune system of cancer patients and 
their effects should be taken in consideration when designing treatment for cancer 
patients (232). It has been described that the immune escape of leukemia may be related 
to inadequate NK cell function such as low NK cell numbers and impaired cytotoxicity. 
In AML,  microvesicles from patient’s sera suppress NK cell activity (233) and 
represent a mechanism by which leukaemia escape form immune system. Most of the 
papers in literature investigated the effects of exosomes on NK cells, while to our 
knowledge no data exist on the possible role of exosomes on γδ T cells function. As NK 
cells, γδ T cells have been know to mediated killing of a broad range of tumor targets, 
including leukaemia blasts. As mentionated before, γδ T cells are able to kill CML cells 
when those cells are pretreated with ZA.  Then the aim of this second part of my thesis 
is to study the effects of exosomes released from K562 CML cell line on γδ T cells to 
better understand the interaction between cancer-exosomes and the immune system. 
Before each experiment I checked the purity of γδ T cells after immunomagnetic 
separation of T cells. The purity of γδ T cells was assessed by flow cytometry. The 
percentage of purified γδ  T cells was 96,7% (Figure 29) 
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Fig. 29: Analysis of  γδT cells isolated by magnetic-activated cell sorting (MACS) using CANTO II. 
a) gate of lymphocytes population based on FSC and SSC parameters; b) CD3+ live subset; c) 
subset of Vγ9+ cells 
 
 
I tested the effect of  exosomes shed by K562 and K562 after treatment with 5 µM of 
zoledronate on cytokines production, NKG2D, CD69 and CD25 expression by γδ T 
cells. Exosomes don’t exert any effects on γδ alone (data not shown), but they are able 
to induce a down-regulation of activation marker, CD69 and CD25, and NKG2D 
expression when γδ T cells are activated with 10 nM of HMBPP and 20 U/ml of IL2. 
Exosomes affect also the IFNγ and TNFα  release, suggesting that exosomes from CML 
have an inhibitory effect on γδ T lymphocytes.  
 
Tumor exosomes inhibit IFNγ and TNFα release 
 
γδ T cells is a subset of lymphocytes able to provide an early source of IFNγ and 
TNFα that are important to kill transformed cells and contribute to the prompt 
generation of adaptive immune responses with αβ T lymphocytes. I investigated the 
effect of exosomes on cytokine release. γδ T cells from healthy donors were treated with 
different doses of  K562 and K562zol exosomes (1,5,10 µg/ml) in presence of 10 nM of 
HMBPP and 20 U/ml of IL2. After overnight incubation, lymphocytes were treated with 
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brefeldin for 4 hr and analyzed for IFNγ and TNFα expression (gating scheme is shown 
Fig. 30). 
 
 
Fig. 40: Schematic representation of the multicolor flow cytometry gating scheme used to analyze 
lymphocyte IFNγ and TNFα expression. a) Vγ9+ CD3+ cells gated; b) γδ+HMBPP+IL2 used as 
control shows 70% IFNγ double positive cells and 53,28% TNFα positive cells; 
c)γδ+HMBPP+IL2+10 µg/ml of K562 exosomes shows a decrease in both cytokines expression 
(48,4% for IFNγ and 17,9% for TNFα); d) γδ+HMBPP+IL2+10 µg/ml of K562zol exosomes shows a 
decrease as K562 exosomes without treatment (56,4% for IFNγ and 16,43% for TNFα); 
 
 
Treatment with K562 and K562zol exosomes induces an impairment in both IFNγ and 
TNFα secreting cells. In figure 31, the graph shows a dose-dependent decrease in 
IFNγ release compared to control.  
Also for TNFα the treatment with exosomes induces a dose-dependent decrease 
(fig.32). 
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Fig. 31: Treatment of γδ+HMBPP+IL2 with 1,5,10 µg/ml of exosomes from K562 and K562 treated 
with 5 µM zoledronic acid induce a dose-dependent decrease in IFNγ release, compared to control 
(γδ+HMBPP+IL2). Data represent mean ± SD of three independent experiments. 
 
 
Interestingly, the treatment with K562zol exosomes seems have a less effect on the 
decrease of TNFα  production compared to treatment with K562 exosomes, especially 
with the dose of 1 µg/ml (23,8% of TNFα after treatment with 1 µg/ml of K562 
exosomes and 29,6% of TNFα after treatment with 1 µg/ml of K562zol). 
 
 
Fig. 32: Treatment of γδ+HMBPP+IL2 with 1,5,10 µg/ml of exosomes from K562 and K562 treated 
with 5 µM zoledronic acid induce a dose-dependent decrease in TNFα release, compared to control 
(γδ+HMBPP+IL2). Data represent mean ± SD of three independent experiments. 
 
 
IFNγ and TNFα produced by γδ T cells are critical cytokines for protective immune 
responses against tumors. The treatment with exosomes induces an inhibition on 
cytokines production in γδ T cells, then impair the ability of these cells to provide an 
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early source of IFNγ in tumor immunosurveillance, and probably on cytotoxicity 
activity of γδ T cells. These data suggest that tumor exosomes express specific 
molecules that mediate the inhibition of  γδ T cell activation. The identification of these 
molecules will be of importance in the future design of successful cancer immune 
therapy. 
 
Exosomes downregulate NKG2D receptor 
 
NKG2D receptor is an activatory receptor of NK, CD8+ and γδ T cells. Elevated levels 
of NKG2D ligands have been documented in a range of epithelial and other 
malignancies (234), and are important in tumor immune surveillance (235). These 
ligands  include members of the MICA and UL16-binding protein (ULBP) families, 
molecules that have highly restricted expression patterns in health, but are readily up-
regulated following viral infection or genotoxic stress (236). The presence of these 
ligands essentially making cancer cells as attractive targets for NK cells (237), γδ T cells 
(238) and CD8+ lymphocytes (239),  through NKG2D-mediated lymphocyte activation 
via PI3K and IFNγ release. Clayton et al, described that exosomes from prostate cancer 
and mesothelioma express NKG2D ligands and are able to downregulate NKG2D 
receptor on NK cells (106). I investigated the effects of exosomes from K562 leukaemia 
cell line on NKG2D receptor on γδ T cells, in order to explain the decrease on cytokine 
production. γδ T cells plus 10 nM of HMBPP and 20 U/ml of IL2 were treated with 
1,5,10 µg/ml of K562 exosomes and K562 zol exosomes. After overnight incubation, 
expression of NKG2D was analyzed by multicolour flow cytometry. Tumor-exosome 
treatment resulted in a significant reduction in cell surface NKG2D expression as shown 
in figure 33. Exosomes treatment don’t change the percentage of NKG2D positive cells. 
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Fig. 33: Treatment of γδ+HMBPP+IL2 with 1,5,10 µg/ml of exosomes from K562 and K562 treated 
with 5 µM zoledronic acid induce a dose-dependent downregulation of NKG2D receptor, compared 
to control (γδ+HMBPP+IL2). Data represent mean ± SD of three independent experiments. 
 
 
This data show that exosomes drive a down-modulation of NKG2D expression,  and 
this can be an important mechanism by which tumor exosomes may suppress this key 
tumor cell recognition and lymphocyte activation pathway. It was described that K562 
CML cell line express MICA,  MICB, ULBP-1, and ULBP-2 ligands at the cell surface  
and in CML patient’s sera was found a soluble form of MICA at high levels (240), while 
such molecules are not detectable in healthy donors sera. The production of NKG2D-
ligand-bearing exosomes, therefore, may be a novel mechanism for tumor cell immune 
evasion, and further demonstrates the complexity of interactions possible between 
exosomes and the immune system. 
 
 CML exosomes downregulate CD69/CD25 expression 
 
Purified γδ T cells rapidly express activation antigens CD25 (high-affinity IL2Rα chain) 
and CD69 following stimulation with HMBPP or IPP. CD69 and CD25 are  involved in 
lymphocytes proliferation and activation. CD69 has a functional role in redirected lysis 
mediated by activated NK and γδ T cells. In figure 34, the graph show that the treatment 
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with exosomes induce a dose-dependent decrease in γδ T cells expressing both 
activation marker. 
 
 
 
Fig. 34: Treatment of γδ+HMBPP+IL2 with 1,5,10 µg/ml of exosomes from K562 and K562 treated 
with 5 µM zoledronic acid induce a dose-dependent downregulation of CD69/CD25 positive cells, 
compared to control (γδ+HMBPP+IL2). Data represent mean ± SD of three independent 
experiments. 
 
 
It was described that downregulation of NKG2D don’t affect the expression of CD69, 
responsible also for NK cells activation, infact in NK cells, treatment with 
mesothelioma exosomes induces upregulation of CD69 (106). Here, treatment with 
K562 exosomes induces a downregulation of this marker and maybe responsible of  the 
lack of  γδ T cells activation. Normally, IL2 induces the expression of CD25, that is 
important for lymphocytes proliferation, and in the presence of tumor exosomes, this 
CD25 induction is inhibited, suggesting that exosomes are able to impair activation of 
γδ T cells. 
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Conclusion 
 
The data obtained in this thesis have touched upon some issues in exosomes biology, 
particularly on the role of exosomes released from CML cell lines on angiogenesis and  
γδ T cell function. Angiogenesis plays an important role in the development and 
progression of CML. The bone marrow of patients with CML exhibit marked 
neovascularization and increased number of endothelial cells; but little is known about 
how CML cells induce the angiogenic phenotype. Recently, exosomes are described as 
new components that modulate the tumor microenvironment, promoting angiogenesis 
and tumor progression. This thesis provides insights into the role of exosomes in 
angiogenesis process. The data obtained indicate that chronic myeloid leukemia cells 
lines, release exosomes characterized by the presence of HSC70, CD63 and 
acetylcholinesterase. LAMA84 exosomes affect several steps of angiogenesis, 
expression of angiogenic factors, chemoinvasion and adhesion. The data showed that 
treatment of HUVEC cells with increasing doses of LAMA84 exosomes and CML 
patients exosomes induce an increase in cell-adhesion molecules ICAM1 and VCAM1, 
increase in production of IL8, a cytoskeletal reorganization with a concomitant 
translocation of VE-cadherin and β-catenin from cell surface to cytoplasm and nuclei,  
that can contribute to angiogenic process. Interestingly, here was found that IL8 play an 
important role in CML exosomes-mediated angiogenesis. It was demonstrated an 
increased mRNA and protein expression of interleukin-8, in exosomes-stimulated 
HUVEC cells. An ELISA assay evaluated the release of IL8 into HUVEC conditioned 
medium and the data confirmed that there is an increase in the release of IL8 from 
endothelial cells after treatment with exosomes. IL8 was found also in LAMA84 
exosomes. To evaluate the angiogenic potential of LAMA84 exosomes it has been 
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performed an in vitro and in vivo angiogenesis assays. LAMA84, CML patients and 
rIL8 exosomes, induced tubular differentiation of HUVECs and stimulated 
vascularization of Matrigel plugs implanted into nude mice. The addition of IL-8 
neutralizing antibodies to CML exosomes in both assays inhibited the process of 
angiogenesis thus reinforcing the role of IL-8 in exosomes-induced vascularization. The 
results here described contribute to understand tumor-host interaction in CML, with a 
prominent role of IL8 in angiogenic phenotype. For the first time, exosomes released 
from CML cells have been involved as important components leading to endothelium 
activation and angiogenesis.  
On the other hand, the initial study on the effects of γδ T cell shows that exosomes from 
K562, and exosomes from K562 after treatment with zoledronate, are able to inhibit 
some γδ T cells function. For the first time it was demonstrated that exosomes from 
CML cell lines are able to downregulate NKG2D receptor, CD69/CD25 activation 
marker and the production of IFNγ and TNFα, suggesting a role of these exosomes in 
immunosuppression. These data provide few but interesting informations about the 
potential role of exosomes on leukemia immune escape mechanism. To better 
understand how exosomes are able to perform this inhibition will be useful assess the 
presence of FASL, MICA and MICB  or other ligands on exosomes surface and 
evaluate the effects of exosomes on γδ T cells proliferation. In order to confirm that 
exosomes impair activaction marker and cytokine release, will be very interesting to 
evaluate the cytotoxic activity of γδ lymphocytes against CML cells targets following 
exosomes treatment. Another important observation is the effects of zoledronic acid on 
the release of exosomes from K562 cell line. After treatment with 5µM of this drug, the 
amount of exosomes is reduced about 50% compared to exosomes from cells untreated, 
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but the effects on γδ T cells function is the same.  
These initial findings on the role of CML exosomes on γδ T cell shed new light on the 
immune-escape mechanism exosomes-mediated. Focus on the mechanism of action of 
zoledronate in the release of exosomes and if after treatment there are change in the 
quality of exosomes could be important to find some new approaches for CML therapy. 
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